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A B S T R A C T
Background
Femoro-popliteal bypass is implemented to save limbs that might otherwise require amputation, in patients with ischaemic rest pain
or tissue loss; and to improve walking distance in patients with severe life-limiting claudication. Contemporary practice involves grafts
using autologous vein, polytetrafluoroethylene (PTFE) or Dacron as a bypass conduit. This is the second update of a Cochrane review
first published in 1999 and last updated in 2010.
Objectives
To assess the effects of bypass graft type in the treatment of stenosis or occlusion of the femoro-popliteal arterial segment, for above-
and below-knee femoro-popliteal bypass grafts.
Search methods
For this update, the Cochrane Vascular Information Specialist searched the Vascular Specialised Register (13 March 2017) and CEN-
TRAL (2017, Issue 2). Trial registries were also searched.
Selection criteria
We included randomised trials comparing at least two different types of femoro-popliteal grafts for arterial reconstruction in patients
with femoro-popliteal ischaemia. Randomised controlled trials comparing bypass grafting to angioplasty or to other interventions were
not included.
Data collection and analysis
Both review authors (GKA and CPT) independently screened studies, extracted data, assessed trials for risk of bias and graded the
quality of the evidence using GRADE criteria.
Main results
We included nineteen randomised controlled trials, with a total of 3123 patients (2547 above-knee, 576 below-knee bypass surgery). In
total, nine graft types were compared (autologous vein, polytetrafluoroethylene (PTFE) with and without vein cuff, human umbilical
vein (HUV), polyurethane (PUR), Dacron and heparin bonded Dacron (HBD); FUSION BIOLINE and Dacron with external
support). Studies differed in which graft types they compared and follow-up ranged from six months to 10 years.
Above-knee bypass
1Graft type for femoro-popliteal bypass surgery (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
For above-knee bypass, there wasmoderate-quality evidence that autologous vein grafts improve primary patency compared to prosthetic
grafts by 60 months (Peto odds ratio (OR) 0.47, 95% confidence interval (CI) 0.28 to 0.80; 3 studies, 269 limbs; P = 0.005). We
found low-quality evidence to suggest that this benefit translated to improved secondary patency by 60 months (Peto OR 0.41, 95%
CI 0.22 to 0.74; 2 studies, 176 limbs; P = 0.003).
We found no clear difference between Dacron and PTFE graft types for primary patency by 60 months (Peto OR 1.67, 95% CI 0.96 to
2.90; 2 studies, 247 limbs; low-quality evidence). We found low-quality evidence that Dacron grafts improved secondary patency over
PTFE by 24 months (Peto OR 1.54, 95% CI 1.04 to 2.28; 2 studies, 528 limbs; P = 0.03), an effect which continued to 60 months
in the single trial reporting this timepoint (Peto OR 2.43, 95% CI 1.31 to 4.53; 167 limbs; P = 0.005).
Externally supported prosthetic grafts had inferior primary patency at 24 months when compared to unsupported prosthetic grafts
(Peto OR 2.08, 95% CI 1.29 to 3.35; 2 studies, 270 limbs; P = 0.003). Secondary patency was similarly affected in the single trial
reporting this outcome (Peto OR 2.25, 95% CI 1.24 to 4.07; 236 limbs; P = 0.008). No data were available for 60 months follow-up.
HUV showed benefits in primary patency over PTFE at 24 months (Peto OR 4.80, 95% CI 1.76 to 13.06; 82 limbs; P = 0.002). This
benefit was still seen at 60 months (Peto OR 3.75, 95% CI 1.46 to 9.62; 69 limbs; P = 0.006), but this was only compared in one trial.
Results were similar for secondary patency at 24 months (Peto OR 4.01, 95% CI 1.44 to 11.17; 93 limbs) and at 60 months (Peto OR
3.87, 95% CI 1.65 to 9.05; 93 limbs).
We found HBD to be superior to PTFE for primary patency at 60 months for above-knee bypass, but these results were based on a
single trial (Peto OR 0.38, 95% CI 0.20 to 0.72; 146 limbs; very low-quality evidence). There was no difference in primary patency
between HBD and HUV for above-knee bypass in the one small study which reported this outcome.
We found only one small trial studying PUR and it showed very poor primary and secondary patency rates which were inferior to
Dacron at all time points.
Below-knee bypass
For bypass below the knee, we found no graft type to be superior to any other in terms of primary patency, though one trial showed
improved secondary patency of HUV over PTFE at all time points to 24 months (Peto OR 3.40, 95% CI 1.45 to 7.97; 88 limbs; P =
0.005).
One study compared PTFE alone to PTFE with vein cuff; very low-quality evidence indicates no effect to either primary or secondary
patency at 24 months (Peto OR 1.08, 95% CI 0.58 to 2.01; 182 limbs; 2 studies; P = 0.80 and Peto OR 1.22, 95% CI 0.67 to 2.23;
181 limbs; 2 studies; P = 0.51 respectively)
Limited data were available for limb survival, and those studies reporting on this outcome showed no clear difference between graft
types for this outcome. Antiplatelet and anticoagulant protocols varied extensively between trials, and in some cases within trials.
The overall quality of the evidence ranged from very low to moderate. Issues which affected the quality of the evidence included
differences in the design of the trials, and differences in the types of grafts they compared. These differences meant we were often only
able to combine and analyse small numbers of participants and this resulted in uncertainty over the true effects of the graft type used.
Authors’ conclusions
There was moderate-quality evidence of improved long-term (60 months) primary patency for autologous vein grafts when compared
to prosthetic materials for above-knee bypasses. In the long term (two to five years) there was low-quality evidence that Dacron confers
a small secondary patency benefit over PTFE for above-knee bypass. Only very low-quality data exist on below-knee bypasses, so we
are uncertain which graft type is best. Further randomised data are needed to ascertain whether this information translates into an
improvement in limb survival.
P L A I N L A N G U A G E S U M M A R Y
Choice of bypass graft material for lower-limb arterial bypasses
Background
A person with severely diseased arteries in one or both legs can experience pain on walking (intermittent claudication), pain at rest,
or death of tissues in the leg. When the main thigh artery has a long blockage, the best option is to insert a bypass to carry the blood
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from an artery with good blood flow to the affected artery below the blockage. Bypass is intended to improve walking, or to save
limbs that might otherwise require amputation. The different types of material available to create the bypass include the person’s own
vein (autologous vein), human umbilical vein, and the prosthetic materials polytetrafluoroethylene (PTFE) or Dacron, alone or with
the blood thinning agent heparin bonded to the inside of the graft. Bypass grafts extending to below the knee are not as effective at
remaining patent (open) with good blood flow as those above the knee. The aim of this review was to determine the most effective type
of material to use for above-knee and below-knee bypass grafts.
Study characteristics and key results
We identified 19 randomised controlled trials that included a total of 3123 people. Of these people, 2547 were given above-knee bypass
grafts and 576 were given bypass grafts below the knee. The evidence in our review is current until 13 March 2017. From our analysis,
we found that grafts made from a person’s own vein had a better primary patency (blood flow) rate than the prosthetic materials PTFE
or Dacron for above-knee bypass grafts. Meanwhile, Dacron (and possibly also human umbilical vein) achieved better blood flow
(patency) than PTFE. We also found that Dacron with supporting rings around it (designed to prevent external compression) showed
worse patency than non-supported Dacron when used in grafts above the knee.
Adding a ’cuff ’ of vein did not improve the patency of PTFE for grafts extending to below the knee. The included trials provided few
results on how long people’s limbs survived following the bypass procedure. There was not much consistency between the trials (and
sometimes within the trials) with regards to people taking additional medications such as antiplatelets or anticoagulants, and this might
have affected the results.
Quality of the evidence
The overall quality of the evidence ranged from very low to moderate. Issues which affected the quality of the evidence included
differences in the design of the trials, and differences in the types of grafts they compared. These differences meant we were often only
able to combine and analyse small numbers of participants and this resulted in uncertainty over the true effects of the graft type used.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Autologous vein compared to other graft types for above-knee femoro-popliteal bypass surgery
Patient or population: people with peripheral vascular disease requiring above-knee femoro-popliteal bypass surgery
Setting: hospital
Intervention: autologous vein
Comparison: other graf t types
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of limbs
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with other graft
types
Risk with autologous
vein
Primary patency
(24 months)
Study populat ion OR 0.59
(0.37 to 0.94)
422
(4 RCTs)
⊕⊕©©
LOW 12
92 fewer autologous vein
graf ts per 1000 (10 to
152 graf ts per 1000)
lose primary patency by
24 months compared to
other graf ts studied
275 per 1000 183 per 1000
(123 to 263)
Primary patency
(60 months)
Study populat ion OR 0.47
(0.28 to 0.80)
269
(3 RCTs)
⊕⊕⊕©
MODERATE 3
172 fewer autologous
vein graf ts per 1000 (54
to 264 graf ts per 1000)
lose primary patency by
60 months compared to
other graf ts studied
451 per 1000 279 per 1000
(187 to 397)
Secondary patency
(60 months)
Study populat ion OR 0.41
(0.22 to 0.74)
176
(2 RCTs)
⊕⊕©©
LOW 12
213 fewer autologous
vein graf ts per 1000 (75
to 330 graf ts per 1000)
lose secondary patency
by 60 months compared
to other graf ts studied
526 per 1000 313 per 1000
(196 to 451)
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Limb salvage - - - - - No studies of these graf t
types reported on this
outcome
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; OR: Odds rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded due to serious risk of bias result ing f rom lack of blinding and poor randomisat ion techniques
2 Downgraded due to imprecision because results based on small t rials with few part icipants and events
3 Downgraded due to risk of bias result ing f rom lack of blinding and poor randomisat ion techniques. We did not downgrade
further for imprecision because the ef fect was large and highly consistent between studies
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B A C K G R O U N D
Description of the condition
Femoro-popliteal bypass grafting for lower limb ischaemia is one
of themost common procedures undertaken by vascular surgeons.
Since its inception in the 1940s the procedure has evolved sig-
nificantly in terms of technical intricacy, graft type, anticoagulant
medication use and patient selection. Various graft types have been
used, including: autologous vein (in situ or reversed), human um-
bilical vein (HUV), synthetic polymers, polytetrafluoroethylene
(PTFE) and Dacron; and more recently heparin-bonded synthetic
polymers.
During femoro-popliteal bypass grafting, the proximal anastomo-
sis is taken from the common, superficial or profunda femoris
artery and the distal anastomosis may be to the popliteal artery
either above or below the knee (referred to as above- and below-
knee grafts).
Description of the intervention
Controversy still exists over the most appropriate type of graft to
use in bypass surgery. It is generally accepted that autologous vein
should be used wherever possible, but there are surgeons who be-
lieve that using vein is a more demanding and time-consuming
operation that involves a longer duration of anaesthesia in rela-
tively frail patients. When vein is unavailable there are widespread
differences in the material used. This is due, in part, to a lack of
relevant randomised evidence. Early trials did not separate above-
and below-knee grafts, were underpowered, had inadequate ran-
domisation and the patient populations were less relevant to mod-
ern practice. As new materials became available they were imple-
mented as standard practice for many surgeons, but with a lack of
high-quality supporting evidence. Even fairly recentmeta-analyses
have relied heavily on non-randomised, retrospective data (Pereira
2006).
How the intervention might work
Arterial bypass grafting works by routing arterial blood around
blocked or narrow sections of artery using an alternative conduit.
This conduit may either be a section of the patient’s own vein
(reversed or with the valves cut and disrupted); or an alternative
biological conduit such as human umbilical vein; or an artificial
material.
Why it is important to do this review
Outcomes from infrainguinal bypass grafting continue to be poor;
at a median follow-up of five years, the landmark randomised trial
comparing bypass surgery to angioplasty in severe limb ischaemia
reported overall survival of less than 50% (Bradbury 2010). There
are economic and patient advantages to successful bypass grafting
(Luther 1997; Perler 1995). When this is considered in the con-
text of the controversy surrounding choice of graft material and
differences in surgical practice, it is vital to make decisions based
on the best evidence currently available.
O B J E C T I V E S
To assess the effects of bypass graft type in the treatment of stenosis
or occlusion of the femoro-popliteal arterial segment, for above-
and below-knee femoro-popliteal bypass grafts.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) comparing at
least two different graft types. All graft types were eligible for
inclusion.
Types of participants
We included patients with femoro-popliteal ischaemia requiring
arterial reconstruction. These were mainly patients with critical
claudication, rest pain or tissue loss (Rutherford category 3 to 6
Consensus Document), but could also include some stable clau-
dicants (Rutherford grade 1 to 2) in earlier trials. Trials in which
a clear distinction was not made between patients receiving grafts
to the popliteal artery and to the tibial arteries were excluded.
For trials analysing above- and below-knee procedures together,
trialists were contacted for data and excluded if the results were
inseparable.
Types of interventions
We included studies comparing two or more graft materials. Ran-
domised controlled trials comparing bypass grafting to angioplasty
or to other interventions were not included.
Types of outcome measures
Primary outcomes
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• Primary patency, defined as continuous patency of the graft
without need for further intervention (including primary assisted
patency if performed during the primary procedure)
Secondary outcomes
• Secondary patency, defined as continuous patency of the
graft, with or without further procedures such as angioplasty or
surgical patching to prevent occlusion
• Limb survival or limb salvage
We assessed these outcomes at three months, six months, one year,
two years, three years and five years after surgery.
Search methods for identification of studies
We placed no restrictions on language.
Electronic searches
For this update, the Cochrane Vascular Information Specialist
(CIS) searched the following databases for relevant trials:
• the Cochrane Vascular Specialised Register (13 March
2017);
• the Cochrane Central Register of Controlled Trials
(CENTRAL (2017, Issue 2)) via the Cochrane Register of
Studies Online.
See Appendix 1 for details of the search strategy used to search
CENTRAL.
The Cochrane Vascular Specialised Register is maintained by the
CIS and is constructed from weekly electronic searches of MED-
LINE Ovid, EMBASE Ovid, CINAHL, AMED, and through
handsearching relevant journals. The full list of the databases,
journals and conference proceedings which have been searched, as
well as the search strategies used are described in the Specialised
Register section of the Cochrane Vascular module in theCochrane
Library (www.cochranelibrary.com).
The CIS also searched the following trial registries for details of
ongoing and unpublished studies (13March 2017); See Appendix
2 for details.
• ClinicalTrials.gov (www.clinicaltrials.gov)
• World Health Organization International Clinical Trials
Registry Platform (www.who.int/trialsearch)
• ISRCTN Register (www.isrctn.com/)
Searching other resources
We searched the reference lists of relevant articles identified
through the electronic searches to identify further trials.
Data collection and analysis
Selection of studies
For this update, both review authors (GKA and CPT) indepen-
dently selected trials for inclusion in the review. The section
’Criteria for considering studies for this review’ details the inclu-
sion criteria used for the selection process.
Data extraction and management
Data were independently extracted by GKA then cross checked
by CPT. The following information was extracted on each trial.
• Trial methods: method of randomisation, method of
allocation.
• Participants: country of origin, age, sex distribution,
severity of disease as measured by the ankle brachial index (ABI)
and the European Consensus definition of critical ischaemia
(Consensus Document), presence of diabetes, inclusion and
exclusion criteria.
• Interventions: type of graft, level of anastomosis, use of
aspirin or anticoagulants, smoking habit after surgery, attendance
at a graft surveillance programme.
• Outcomes: primary and secondary patency, limb survival.
Assessment of risk of bias in included studies
For this update, both review authors independently assessed the
risk of bias in the included studies according to the guidelines
given in the Cochrane Handbook for Systematic Reviews of Inter-
ventions, (Higgins 2011). We assessed the new studies included in
the updated review and we re-assessed the studies already included
from the previous versions of the review.
We assessed the following domains as low risk of bias, unclear risk
of bias, or high risk of bias:
• sequence generation;
• allocation concealment;
• blinding of participants and personnel;
• blinding of outcome assessment;
• incomplete outcome data;
• selective outcome reporting;
• other bias.
These assessments are reported for each individual study in the
Characteristics of included studies tables.
Measures of treatment effect
Wepresented the results from the dichotomous outcomes (primary
or secondary patency; limb salvage) as odds ratios (ORs) with 95%
confidence intervals (CIs).
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Unit of analysis issues
The unit of analysis was the limb. Some participants in some trials
were enrolled more than once, as each lower limb was allowed to
be entered into some of the trials independently. This created a
unit of analysis issue when considering survival with intact limb,
but it was felt that effects on both primary patency (our primary
outcome) and secondary patency would be small, so these trials
were not excluded. None of the included studies allowed previous
bypass in the affected limb. Survival data were only considered
where it was clear that participants could not be enrolled in the
same trial more than once.
Dealing with missing data
Where data were missing we attempted to determine the reasons
for this. If data weremissing due to participants being lost to follow
up or because participants were not followed up to a certain time
point prior to publication (censoring) and reasons were clearly
described, we assumed the data were missing at random.
Assessment of heterogeneity
Heterogeneity was assessed visually (for methodological or clinical
heterogeneity) by inspecting the forest plots and statistically by
using Review Manager 5 software (Higgins 2003). We obtained P
values comparing the test statistic with a Chi2 distribution. The
Chi2 statistic describes the percentage of total variation across stud-
ies due to heterogeneity rather than by chance. A value of 0% indi-
cates no observed heterogeneity and larger values show increasing
heterogeneity.
Assessment of reporting biases
We planned to assess reporting bias by presenting funnel plots
if more than 10 studies were included in the analysis. We also
searched trial registries to look for unreported studies.
Data synthesis
We analysed and presented data into groups according to whether
the distal anastomosis was above or below the knee.
We only undertookmeta-analysis whenwe felt there was no signif-
icant methodological heterogeneity, and statistical heterogeneity
was not revealed by either calculation of I2 or performing Chi2
tests. The effect estimate was calculated using Peto ORs with 95%
CIs. Peto ORs were used as it was anticipated that intervention ef-
fects would mainly be small, and that most trials would have sim-
ilar numbers in experimental and control groups. We used fixed-
effect methods as there was no significant heterogeneity detected.
All analyses were based on endpoint data from the individual clin-
ical trials, which all quoted intention-to-treat results. The data
were synthesised by comparing group results. Individual patient
data from different trials were not amalgamated.
Subgroup analysis and investigation of heterogeneity
We performed subgroup analysis according to graft type.
Sensitivity analysis
We performed sensitivity analysis to consider whether excluding
studies with higher risk of bias led to significant changes in the
results.
Summary of findings
We created ’Summary of findings’ tables using GRADEpro soft-
ware (GRADEpro GDT 2015). The study population consisted
of patients with femoro-popliteal ischaemia requiring arterial re-
construction, and we created tables for the comparisons of ’Autol-
ogous vein compared to other graft types for above-knee femoro-
popliteal bypass surgery’ (Summary of findings for the main
comparison); ’PTFE compared toDacron for above-knee femoro-
popliteal bypass surgery’ (Summary of findings 2); ’Externally sup-
ported Dacron compared to unsupported Dacron for above-knee
femoro-popliteal bypass surgery’ (Summary of findings 3) and
’PTFE compared to PTFE with vein cuff for below-knee femoro-
popliteal bypass surgery’ (Summary of findings 4). The most im-
portant and clinically relevant outcomes (both desirable and un-
desirable) that were thought to be essential for decision-making
were the outcomes primary patency (at 24 and 60 months fol-
low-up), secondary patency (at 60 months follow-up) and limb
salvage (at 24 months follow-up). Assumed control intervention
risks were calculated by the mean number of events in the control
groups of the selected studies for each outcome. We used the sys-
tem developed by the Grades of Recommendation, Assessment,
Development and Evaluation working group (GRADE working
group) for grading the quality of evidence as high, moderate, low
or very low, based on within-study risk of bias, inconsistency, di-
rectness of evidence, imprecision, and publication bias (GRADE
2004; GRADEpro GDT 2015).
R E S U L T S
Description of studies
Results of the search
See Figure 1.
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Figure 1. Study flow diagram.
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Included studies
For summarised details of the included studies, see Characteristics
of included studies.
We included seven additional studies in this review update
(Davidovic 2010; Gloor 1996; Gupta 1991; Lumsden 2015;
SCAMICOS 2010; Solakovic 2008; Vriens 2013), making a total
of 19 randomised controlled trials whichmet the criteria for inclu-
sion (Aalders 1992; Abbot 1997; Ballotta 2003; Davidovic 2010;
Devine 2004; Eickhoff 1987; Gloor 1996; Gupta 1991; Jensen
2007; Klinkert 2003; Lumsden 2015; Post 2001; SCAMICOS
2010; Scharn 2008; Solakovic 2008; Stonebridge 1997; Tofigh
2007; van Det 2009; Vriens 2013). We had excluded three of
the studies from the previous version of this review due to un-
clear randomisationmethods (Gloor 1996;Gupta 1991; Solakovic
2008), but we were able to include them in this version due to
the use of Cochrane’s ’Risk of bias’ tool. Follow-up was reported
to six months (Lumsden 2015), one year (Davidovic 2010; Gloor
1996), two years (Jensen 2007; Post 2001; Scharn 2008; Tofigh
2007; Vriens 2013), three years (Gupta 1991; SCAMICOS2010),
four years (Eickhoff 1987), five years (Aalders 1992; Abbot 1997;
Ballotta 2003; Devine 2004; Klinkert 2003; Solakovic 2008;
Stonebridge 1997) and 10 years (van Det 2009). There were a
total of 3123 patients (2547 above-knee, 576 below-knee), with
bypasses being performed on 3238 limbs (2662 above-knee, 576
below-knee). Nine types of graft were compared: autologous vein;
polytetrafluoroethylene (PTFE) with and without vein cuff and
with or without external support; human umbilical vein (HUV);
Dacron and heparin bondedDacron (HBD); FUSIONBIOLINE
and Dacron with external support).
Above-knee bypass
Two trials compared autologous vein and PTFE grafts above the
knee (Ballotta 2003; Klinkert 2003). In Ballotta 2003, 102 limbs
(51patients)with bilateral disabling claudicationwere randomised
to receive reversed saphenous vein or PTFE. Klinkert 2003 also
compared reversed saphenous veinwith PTFE, in 151 limbs. Anti-
coagulation protocols andmedication checks varied between these
trials; see Characteristics of included studies for details.
In Tofigh 2007 autologous vein was compared with a polyester
graft, while Solakovic 2008 compared autologous vein with a pros-
thetic graft, which was allowed to be either PTFE of Dacron.
These have been considered separately for analysis from those tri-
als where the prosthetic material was more clearly specified.
One trial compared PTFE with HUV in 93 limbs (Aalders 1992).
Five trials compared PTFE with Dacron (Abbot 1997; Davidovic
2010; Jensen 2007; Post 2001; van Det 2009). We did not use
Davidovic 2010 the quantitative analysis due to concerns over risk
of bias in outcome data (see Characteristics of included studies).
The trial with the largest number of limbs was Jensen 2007, in
which 205 PTFE grafts were compared with 208 Dacron grafts.
Unfortunately, anticoagulant and follow-up protocols varied be-
tween departments in this study. In van Det 2009, 114 limbs were
randomised to PTFE and 114 limbs to Dacron; the trialists used
warfarin with a consistent protocol for anticoagulation, and they
continued follow-up for 10 years. One trial compared PTFE with
the FUSION BIOLINE graft (Lumsden 2015), which is a two-
layer graft, the inner layer being heparin-bonded expanded PTFE
(ePTFE)which is glued to an outer knitted polyester textile. Above
the knee, 88 limbs were randomised to FUSION BIOLINE graft,
whilst 86 received standard ePTFE. Gupta 1991 considered PTFE
with or without ringed support; 29 limbs received ringed grafts
and 30 limbs received unringed grafts above the knee.
One trial looked at fluoropolymer-coated Dacron graft with or
without external support (Vriens 2013), with 134 limbs assigned
to externally supported graft and 119 treated with unsupported
graft.
One trial compared PTFE with PTFE and vein cuff in above-
knee bypass (Stonebridge 1997). The study included 74 limbs
with PTFE and 76 with PTFE and vein cuff. The numbers of
continuing smokers and of participants on antiplatelet and antico-
agulant therapy were not given. Peri-operative complications were
not stated.
One study comparedHBDwithHUV (Scharn 2008) and one trial
compared HBD with PTFE (Devine 2004). The anticoagulant
protocol was not stated in the latter (Devine 2004).
One study compared polyurethane (PUR) with Dacron (Gloor
1996). Both primary and secondary patency rates were poor for the
PUR grafts and the trial was stopped early due to safety concerns
after only 20 limbs had been randomised.
Below-knee bypass
There were far less data available for below-knee bypass, with 651
procedures analysed. No studies compared autologous vein with
PTFE, HUV or other graft types. One trial compared PTFE with
Dacron (Post 2001), however there were low numbers of partic-
ipants in each group (26 in the PTFE group, 27 in the Dacron
group). Two trials (Stonebridge 1997; SCAMICOS 2010) com-
pared PTFEwith PTFE and vein cuff. One study (Lumsden 2015)
compared standard ePTFE with the FUSION BIOLINE graft,
though numbers of below-knee popliteal procedures were low in
each group (14 in the FUSIONBIOLINE group, 14 in the PTFE
group). Gupta 1991 included 63 below-knee bypasses, and com-
pared PTFE with or without ringed support in 29 and 34 limbs
respectively.
One study (Eickhoff 1987) compared PTFE with HUV. This trial
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also separately analysed patency rates in claudicants and those with
good distal runoff, and found those patients to have a patency
advantage. The study authors did not state the anticoagulants used.
Devine 2004 gave separate below-knee data.
There were no statistically significant differences in the major co-
founders of sex, age, smoking, dyslipidaemia (abnormal concen-
trations of lipids or lipoproteins in the blood), diabetes or hyper-
tension reported between groups in any of the above- or below-
knee trials.
Excluded studies
For this update, we excluded six additional studies (Lindholt
2011; Linni 2015; Lundgren 2013; Midy 2016; NCT00617279;
NCT00845585); we also excluded a study which had been in-
cluded in previous versions of the review (Watelet 1997). We ex-
cluded three studies because above- and below-the-knee data could
not be separated for analyses (Lindholt 2011, Linni 2015;Watelet
1997) . We excluded Lundgren 2013 because it included a mix-
ture of femoro-popliteal and femoro-tibial bypass patients, and
results for the subset of patients treated with femoro-popliteal by-
pass were not presented separately. We excluded one study (Midy
2016) as it failed to recruit even 30% of the planned number of
patients, and more than 25% of those recruited had no follow-
up. We excluded NCT00617279 and NCT00845585 for similar
reasons; the former trial was terminated by the sponsor due to slow
recruitment and no results were ever presented, whereas the latter
trial was terminated before a single patient was recruited. Full rea-
sons for trials being excluded can be found in the Characteristics
of excluded studies table.
Ongoing studies
We identified two ongoing studies as being relevant to this review
and these may be included in future updates (NCT00205790;
NCT00147979). See Characteristics of ongoing studies.
Risk of bias in included studies
See Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
11Graft type for femoro-popliteal bypass surgery (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
12Graft type for femoro-popliteal bypass surgery (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Overall, the risk of bias was significant, principally due to a lack of
blinding. There were issues to do with attrition and it was unclear
whether there might have been issues of selection bias in some
studies.
Allocation
Random sequence generation
Seven studies were at low risk of bias as their sequence generation
was adequate (Aalders 1992; Ballotta 2003; Devine 2004; Jensen
2007; Post 2001; Scharn 2008; van Det 2009). We judged the
remaining 12 studies to have unclear risk of bias as they failed
to describe the method of randomisation, or used a non-standard
technique (Abbot 1997; Davidovic 2010; Eickhoff 1987; Gloor
1996; Gupta 1991; Klinkert 2003; Lumsden 2015; SCAMICOS
2010; Scharn 2008; Solakovic 2008; Stonebridge 1997; Tofigh
2007; Vriens 2013).
Allocation concealment
Eleven studies had adequate allocation concealment (Ballotta
2003; Devine 2004; Eickhoff 1987; Jensen 2007; Klinkert 2003;
Post 2001; SCAMICOS 2010; Scharn 2008; Solakovic 2008; van
Det 2009; Vriens 2013). The remaining eight were at unclear risk
of bias as allocation concealment was not clearly discussed (Aalders
1992; Abbot 1997; Davidovic 2010; Gloor 1996; Gupta 1991;
Lumsden 2015; Stonebridge 1997; Tofigh 2007).
Blinding
Blinding for graft insertion is impossible in surgical trials of this
nature. Outcome assessment may be blinded, however this was
not the case in any of the included studies and we are unsure
what effect this may have had on the outcomes in question. For
this reason all included studies were judged to be at high risk of
performance bias and at unclear risk of detection bias.
Incomplete outcome data
We judged one study (Abbot 1997) to be at high risk of attri-
tion bias as 13 participants were lost following randomisation and
results were reported without specifically stating what happened
to these participants. Davidovic 2010 failed to present numbers
at risk at different time points and secondary patency was pre-
sented as worse than primary patency, which is impossible. Due to
these issues we judged this study to be at high risk of bias and did
not include it in meta-analysis. We assessed Gloor 1996 as having
unclear risk of bias as they failed to include a CONSORT flow
diagram and there was no mention of patients excluded prior to
randomisation or after randomisation. All the remaining studies
were at low risk of bias, since any losses were minimal or described
clearly.
Selective reporting
One study (Gloor 1996) failed to present details of complications
occurring within the first 30 days which did not lead to reinterven-
tion, though this was a stated secondary outcome. As this is a pa-
tient population with significant comorbidity, it is likely that there
were some undisclosed complications, so we judged the study to
be at unclear risk of reporting bias. There were no concerns over
selective reporting in any of the other included studies.
Other potential sources of bias
Three trials had antiplatelet and anticoagulant protocols which
obviously varied within the trial: Post 2001 used heparin, warfarin
or antiplatelet agents (specific agent not stated); Scharn 2008 used
aspirin or coumarin derivatives; and Jensen 2007 used different
anticoagulation protocols in each centre. One study (Lumsden
2015) left decisions about heparin, protamine and topical haemo-
statics to the operating surgeon, but specified that postoperative as-
pirin therapy was compulsory in all participants. Five trials did not
state their anticoagulation protocol (Abbot 1997; Devine 2004;
Eickhoff 1987; SCAMICOS 2010; Stonebridge 1997).One study
(Solakovic 2008) gave a clear protocol of anticoagulants in the
perioperative period and antiplatelet agents following discharge,
but gave no details of compliance checks. We considered all these
studies to have unclear risk of other sources of bias.
Effects of interventions
See: Summary of findings for the main comparison Autologous
vein compared to other graft types for above-knee femoro-
popliteal bypass surgery; Summary of findings 2PTFE compared
to Dacron for above-knee femoro-popliteal bypass surgery;
Summary of findings 3 Externally supported graft compared to
unsupported graft for above-knee femoro-popliteal bypass surgery;
Summary of findings 4 PTFE compared to PTFE with vein cuff
for below-knee femoro-popliteal bypass surgery
Above-knee bypass
Autologous vein compared to other graft types
Four studies compared autologous veins to other grafts prosthetic
materials (Ballotta 2003; Klinkert 2003; Solakovic 2008; Tofigh
2007).
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Primary patency
We were able to include four trials comparing autologous vein
to prosthetic materials in a meta-analysis (Ballotta 2003; Klinkert
2003; Solakovic 2008; Tofigh 2007). We found no clear differ-
ence between the groups in primary patency at 3, 6 or 12 months.
See Analysis 1.1; Analysis 1.2; Analysis 1.3 respectively. Although
individual trials failed to show clear benefit, once results of the
four trials were combined a long-term benefit for autologous vein
was observed at 24 months (Peto odds ratio (OR) 0.59, 95% con-
fidence interval (CI) 0.37 to 0.94; 422 limbs; 4 studies; P = 0.03;
low-quality evidence; Analysis 1.4). This was reflected in the con-
tinued benefit in primary patency for autologous vein over pros-
thetic grafts by five years (PetoOR0.47, 95%CI 0.28 to 0.80; 269
limbs; 3 studies; P = 0.005; moderate-quality evidence; Analysis
1.5). The comparison with polytetrafluoroethylen (PTFE) con-
tributed the majority of weight to this result (weight 63.6%, OR
0.48, 95% CI 0.25 to 0.95).
Secondary patency
Three studies comparing autologous vein to prosthetic materi-
als reported on this outcome and were pooled in a meta-analysis
(Klinkert 2003; Solakovic 2008; Tofigh 2007). No improvement
in secondary patency was found at 3, 6, 12 or 24 months. See
Analysis 1.6; Analysis 1.7; Analysis 1.8; Analysis 1.9 respectively. A
benefit was seen at five years (Peto OR 0.41, 95% CI 0.22 to 0.74;
176 limbs; 2 studies; P = 0.003; low-quality evidence; Analysis
1.10). However Ballotta 2003 and Tofigh 2007 were not included
in analysis at this timepoint, reducing the power of the compari-
son. There was no evidence of significant statistical heterogeneity
between these trials.
Limb survival or limb salvage
No data available
Polytetrafluoroethylen (PTFE) compared to other graft
types
Eight studies compared PTFE to other grafts (Aalders 1992; Abbot
1997; Davidovic 2010; Jensen 2007; Lumsden 2015; Post 2001;
Stonebridge 1997; van Det 2009).
Primary patency
Of the five studies comparing PTFE with Dacron (Abbot 1997;
Davidovic 2010; Jensen2007; Post 2001; vanDet 2009), fourwere
considered suitable for meta-analysis (Abbot 1997; Jensen 2007;
Post 2001; vanDet 2009).We did not includeDavidovic 2010 be-
cause of concerns about risk of bias (see Incomplete outcome data
(attrition bias)). All four studies reported at 12 and 24months; the
remaining timepoints had data available from one or two studies.
Three studies (Jensen 2007; van Det 2009; Post 2001) showed a
non-significant trend towards a greater benefit with Dacron and
Abbot 1997 showed a non-significant trend in favour of PTFE.
Abbot 1997 was the weakest trial in terms of potential bias; see
Figure 3 and the table Characteristics of included studies.
Once combined, we found no significant difference in primary
patency between PTFE and Dacron at any time point. Removing
the one trial with significant bias issues (Abbot 1997) did not
change this result, except at 60months, where data from one study
(van Det 2009) suggested that Dacron grafts may potentially have
a small benefit in primary patency at this time point (OR 1.87;
95% CI 1.01 to 3.43; Analysis 2.5).
One study (Aalders 1992) compared PTFE with human umbilical
vein (HUV). No difference in primary patency was seen at three
or six months (Analysis 2.1 and Analysis 2.2 respectively). Our
analysis suggests a benefit in primary patency for HUV by 12
months (Peto OR 3.17, 95% CI 1.04 to 9.64; P = 0.04; 83 limbs;
1 study), which continued to 24 months (Peto OR 4.80, 95%
CI 1.76 to 13.06; 82 limbs; 1 study; P = 0.002 (Analysis 2.4)).
This benefit was still evident at five years (Peto OR 3.75, 95% CI
1.46 to 9.62; 69 limbs; 1 study; P = 0.006), Analysis 2.5), but the
results are limited because of small numbers of participants.
In Stonebridge 1997, there was no significant difference between
PTFE and PTFE with vein cuff used above the knee for the out-
come primary patency at any time point (Analysis 2.3; Analysis
2.4).
One study (Lumsden 2015) compared a new graft material, FU-
SION BIOLINE, which is composed of an inner heparin bonded
PTFE layer glued to an outer knitted polyester layer. This study
found a significant improvement in primary patency at six months
for above-knee bypass done with FUSIONBIOLINE, when com-
pared with a standard PTFE graft (Peto OR 2.99, 95% CI 1.43
to 6.26; 174 limbs; 1 study; P = 0.004; Analysis 2.2) . Results
reported at other time points were only presented for both above-
and below-knee grafts combined, and failed to show a significant
difference at either 90 days or 12 months, though the results at six
months were also significant in the combined analysis.
Secondary patency
There was no clear difference in secondary patency between PTFE
and Dacron at 6 months (Peto OR 1.01, 95% CI 0.25 to 4.13;
225 limbs; 1 study) or 12 months (Peto OR 1.19, 95% CI 0.76
to 1.86; 581 limbs; 2 studies). See Analysis 2.7 and Analysis 2.8.
A benefit from the use of Dacron grafts was seen at 24 months
(Peto OR 1.54, 95% CI 1.04 to 2.28; 528 limbs; 2 studies; P =
0.03) and 60 months (Peto OR 2.43, 95% CI 1.31 to 4.53; 167
limbs; 1 study; P = 0.005). See Analysis 2.9 and Analysis 2.10.
In Stonebridge 1997, there was no significant difference between
PTFE and PTFE with vein cuff used above the knee for the out-
come secondary patency at any time point (Analysis 2.8; Analysis
2.9).
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One study (Aalders 1992) compared PTFE with human umbil-
ical vein (HUV). No clear difference in secondary patency was
seen at three, six and 12 months (Analysis 2.6; Analysis 2.7 and
Analysis 2.8 respectively). Our analysis suggests a benefit in sec-
ondary patency for HUV by 24 months (Peto OR 4.01, 95% CI
1.44 to 11.17; 93 limbs; 1 study; P = 0.008), which continued
to 60 months (Peto OR 3.87, 95% CI 1.65 to 9.05; 93 limbs; 1
study; P = 0.002) (Analysis 2.10).
Limb survival or limb salvage
Only two studies reported detailed limb salvage rates for above-
knee femoro-popliteal bypass (Jensen 2007; Stonebridge 1997).
Jensen 2007 compared PTFE with Dacron and Stonebridge 1997
compared PTFE with PTFE and vein cuff. Neither found differ-
ences in limb salvage rates between graft types at one month or 24
months (Analysis 2.11; Analysis 2.12).
Heparin bonded Dacron (HBD) versus other grafts
Two studies compared heparin bonded Dacron grafts with other
grafts (Devine 2004; Scharn 2008). Devine 2004 compared hep-
arin bonded Dacron to PTFE and Scharn 2008 compared HBD
to HUV.
Primary patency
In Devine 2004, no difference in patency was detected at 12 or
24 months, though by 60 months, HBD showed improved pa-
tency compared to PTFE (Peto OR 0.38, 95% CI 0.20 to 0.72;
146 limbs; 1 study; P = 0.003). In Scharn 2008 there was no im-
provement in primary patency at any time interval when HBD
was compared to HUV.
The combined overall primary patency for HBD compared to
HUV/PTFE was improved at 12 months (Peto OR 0.58, 95% CI
0.34 to 0.98; 294 limbs; 2 studies); 24 months (Peto OR 0.62,
95% CI 0.38 to 1.02; 282 limbs; 2 studies); and 60 months (Peto
OR 0.55, 95%CI 0.33 to 0.93; 232 limbs; 2 studies). See Analysis
3.1 to Analysis 3.3.
Secondary patency
No data available
Limb survival or limb salvage
No data available
Externally-supported Dacron or PTFE grafts compared to
other grafts
One trial examined whether adding external support to Dacron
might improve outcomes in above-knee femoro-popliteal bypass
(Vriens 2013), while another considered the same question for
PTFE grafts (Gupta 1991).
Primary patency
Although short-term primary patency rates were comparable (
Analysis 4.1; Analysis 4.2), by 24 months the externally supported
Dacron grafts showed worse primary patency when compared to
their unsupported counterparts (Peto OR 2.09, 95% CI 1.26 to
3.46; 240 limbs; 1 study; P = 0.004; Analysis 4.3).
Results from Gupta 1991 showed similar primary patency for
PTFE grafts with and without ringed support at 6, 12 and 24
months (Analysis 4.1; Analysis 4.2; Analysis 4.3).
Secondary patency
Although short-term secondary patency rates were comparable, by
24 months the externally supported Dacron grafts showed worse
secondary patency when compared to their unsupported counter-
parts (Peto OR 2.25, 95% CI 1.24 to 4.07; 236 limbs; 1 study; P
= 0.008; Analysis 4.6).
Limb survival or limb salvage
No data available
Polyurethane (PUR) graft compared to other grafts
One trial examined a new PUR graft type (Gloor 1996).
Primary patency
Primary patency was worse for the PUR grafts at all time points
and the trial was stopped due to safety concerns after only 20 limbs
had been randomised. See Analysis 5.1; Analysis 5.2; Analysis 5.3.
Secondary patency
Secondary patency was worse for the PUR grafts at all time points
and the trial was stopped due to safety concerns after only 20 limbs
had been randomised. See Analysis 5.4; Analysis 5.5; Analysis 5.6.
Limb survival or limb salvage
No data available
Below-knee bypass
PTFE compared to other graft types
Six studies reported on primary or secondary patency, or both, but
analysis was limited by different graft comparisons and reporting
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at different timepoints (Eickhoff 1987; Gupta 1991; Lumsden
2015; Post 2001; SCAMICOS 2010; Stonebridge 1997).
Primary patency
There was no clear difference in primary patency for PTFE com-
pared to Dacron at 12 months (Peto OR 0.47, 95% CI 0.12 to
1.79; P = 0.27; 45 limbs; 1 study; Analysis 6.2) and 24 months
(Peto OR 0.41, 95% CI 0.12 to 1.42; 40 limbs; 1 study; P = 0.16;
Analysis 6.3), however the analysis only included one trial (Post
2001).
The two trials comparing PTFE with a vein cuff to PTFE
alone in below-knee femoro-popliteal bypass were heterogeneous:
Stonebridge 1997 suggested a benefit with the addition of a vein
cuff, whilst SCAMICOS 2010 favoured no cuff. Pooling the data
showed no difference in primary patency at six, 12 and 24 months
(24 months: Peto OR 1.08, 95% CI 0.58 to 2.01; 182 limbs;
2 studies; Analysis 6.3). Allocation concealment and random se-
quence generation were not clearly described in Stonebridge 1997,
so results may be attributable to selection bias in that trial.
One study (Gupta 1991) considered whether ringed support was
of benefit in PTFE grafts below the knee. We found no difference
of effect at any time point (Analysis 6.2).
A small number of patients in the FUSIONBIOLINE trial had be-
low-knee bypass (Lumsden 2015).We found no significant differ-
ence in primary patency between FUSION BIOLINE and PTFE
in this case (Analysis 6.1).
Secondary patency
One trial provided results on below-the-knee secondary patency
for PTFE versus HUV (Eickhoff 1987).This trial showed im-
proved patency rates for HUV grafts at all time intervals from
three months to 24 months. See Analysis 6.5 to Analysis 6.8 (24
months: PetoOR3.40; 95%CI 1.45 to 7.97, P = 0.005; 88 limbs;
1 study).
The two trials comparing PTFE with a vein cuff to PTFE
alone in below-knee femoro-popliteal bypass were heterogeneous
(SCAMICOS 2010; Stonebridge 1997). Pooling the data showed
no difference in secondary patency at 12 and 24 months (24
months: (Peto OR 1.22, 95% CI 0.67 to 2.23; 181 limbs; 2 stud-
ies; Analysis 6.8). Allocation concealment and random sequence
generation were not clearly described in Stonebridge 1997, so re-
sults may be attributable to selection bias in that trial.
Limb survival or limb salvage
Limited information was available on limb survival for be-
low-knee femoro-popliteal bypass. Only Stonebridge 1997 and
SCAMICOS 2010 reported this outcome, for PTFE versus PTFE
with vein cuff. They found no clear difference at 12 months (Peto
OR1.35, 95%CI 0.72 to 2.55; 225 limbs; 2 studies) or 24months
(PetoOR1.34, 95%CI0.72 to 2.49; 196 limbs; 2 studies; Analysis
6.10 and Analysis 6.11).
Heparin bonded Dacron versus all other graft materials
Primary patency
Only Devine 2004 compared HBD grafts with other grafts. No
clear differences in primary patency were observed between HBD
and PTFE below the knee at any time interval in this study (
Devine 2004; Analysis 7.1; Analysis 7.2; Analysis 7.3; Analysis
7.4; Analysis 7.5).
Secondary patency
No data available
Limb survival or limb salvage
No data available
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
PTFE compared to Dacron for above-knee femoro-popliteal bypass surgery
Patient or population: people with peripheral vascular disease requiring above-knee femoro-popliteal bypass surgery
Setting: hospital
Intervention: PTFE
Comparison: Dacron
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of limbs
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with Dacron Risk with PTFE
Primary patency
(24 months)
Study populat ion OR 1.23
(0.92 to 1.65)
764
(4 RCTs)
⊕⊕©©
LOW 12
Our conf idence in the ef -
fect is lim ited and this
may dif fer substant ially
f rom the est imate of the
ef fect
404 per 1000 454 per 1000
(384 to 528)
Primary patency
(60 months)
Study populat ion OR 1.67
(0.96 to 2.90)
247
(2 RCTs)
⊕⊕©©
LOW 12
Our conf idence in the ef -
fect is lim ited and this
may dif fer substant ially
f rom the est imate of the
ef fect
606 per 1000 720 per 1000
(597 to 817)
Secondary patency
(24 months)
Study populat ion OR 1.54
(1.04 to 2.28)
528
(2 RCTs)
⊕⊕©©
LOW 12
81 more PTFE graf ts
per 1000 (7 to 168 per
1000) suf fer f rom failed
secondary patency by
24 months compared to
Dacron
212 per 1000 293 per 1000
(219 to 380)
Limb salvage
(24 months)
Study populat ion OR 0.82
(0.27 to 2.48)
322
(1 RCT)
⊕⊕©©
LOW 12
Our conf idence in the ef -
fect is lim ited and this
may dif fer substant ially
f rom the est imate of the
ef fect
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44 per 1000 37 per 1000
(12 to 103)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; OR: Odds rat io;PTFE: polytetraf luoroethylene
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded because of serious risk of bias due to lack of blinding and poor randomisat ion techniques
2 Downgraded due to imprecision because of the low number of part icipants and events
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Externally supported graft compared to unsupported graft for above-knee femoro-popliteal bypass surgery
Patient or population: people with peripheral vascular disease requiring above-knee femoro-popliteal bypass surgery
Setting: hospital
Intervention: externally supported graf t
Comparison: unsupported graf t
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of limbs
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with unsupported
graft
Risk with externally
supported graft
Primary patency
(24 months)
Study populat ion OR 2.08
(1.29 to 3.35)
270
(2 RCTs)
⊕⊕©©
LOW 12
180 fewer unsupported
prosthet ic graf ts per
1000 (61 to 293 graf ts
per 1000) lose pri-
mary patency by 24
months compared to ex-
ternally supported pros-
thet ic graf ts
376 per 1000 556 per 1000
(437 to 669)
Primary patency
(60 months)
- - - - - No studies comparing
supported and unsup-
ported Dacron reported
on primary patency at 60
months
Secondary patency
(24 months)
Study populat ion OR 2.25
(1.24 to 4.07)
236
(1 RCT)
⊕⊕©©
LOW 12
143 fewer unsupported
Dacron graf ts per 1000
(32 to 281 graf ts per 1,
000) lose secondary pa-
tency by 24 months com-
pared to externally sup-
ported Dacron graf ts
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165 per 1000 308 per 1000
(197 to 446)
Limb salvage - - - - - No studies of these graf t
types reported on this
outcome
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded because of serious risk of bias due to lack of blinding and poor randomisat ion techniques
2 Downgraded due to imprecision because of the low number of part icipants and events
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PTFE compared to PTFE with vein cuff for below-knee femoro-popliteal bypass surgery
Patient or population: people with peripheral vascular disease requiring below-knee femoro-popliteal bypass surgery
Setting: hospital
Intervention: PTFE
Comparison: PTFE with vein cuf f
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of limbs
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with PTFE with
vein cuff
Risk with PTFE
Primary patency
(24 months)
Study populat ion OR 1.08
(0.58 to 2.01)
182
(2 RCTs)
⊕©©©
VERY LOW 123
Findings f rom two small
t rials were inconsistent
so our conf idence in the
ef fect is lim ited and this
may dif fer substant ially
f rom the est imate of the
ef fect
626 per 1000 644 per 1000
(493 to 771)
Primary patency
(60 months)
- - - - - No studies comparing
PTFE with and without
a vein cuf f for below-
knee bypass reported on
primary patency at 60
months
Secondary patency
(24 months)
Study populat ion OR 1.22
(0.67 to 2.23)
181
(2 RCTs)
⊕©©©
VERY LOW 123
Findings f rom two small
t rials were inconsistent
so our conf idence in the
ef fect is lim ited and this
may dif fer substant ially
f rom the est imate of the
ef fect
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557 per 1000 605 per 1000
(457 to 737)
Limb salvage
(24 months)
Study populat ion OR 1.34
(0.72 to 2.49)
196
(2 RCTs)
⊕⊕©©
LOW 13
Our conf idence in the ef -
fect is lim ited and this
may dif fer substant ially
f rom the est imate of the
ef fect
266 per 1000 327 per 1000
(207 to 474)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; OR: Odds rat io;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded due to serious risk of bias result ing f rom lack of blinding and poor randomisat ion techniques
2 Downgraded due to signif icant heterogeneity in studies
3 Downgraded due to imprecision because of the low number of part icipants and events
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D I S C U S S I O N
Summary of main results
Our major findings were that autologous vein grafts have long-
term patency benefits over prosthetic grafts in above-knee femoro-
popliteal bypass (moderate-quality evidence). In the long term
(greater than two years), we found that Dacron may confer a slight
benefit in secondary patency over polytetrafluoroethylene (PTFE)
for above-knee bypasses (low-quality evidence). There was no sig-
nificant improvement in primary and secondary patency for be-
low-knee PTFE bypasses when a vein cuff was included. Limited
evidence was available on below-knee procedures for all graft types.
There was also limited evidence on limb survival for both above-
and below-knee bypass surgery.
Overall completeness and applicability of
evidence
While there have been many randomised controlled trials con-
ducted for lower limb bypass surgery, the overall quality of
these was poor and meant that we had to exclude 24 trials (see
Characteristics of excluded studies). Some of the main reasons we
excluded trials were because they failed to randomise patients, they
did not report the data for above- and below-knee procedures sep-
arately, or because they had severe methodological flaws which led
to significant bias within the trial.
We only found low numbers of trials for some analyses, especially
for below-knee bypass, which is partly indicative of the numbers
of new graft types being introduced and partly indicative of the re-
duced numbers of lower-limb bypass procedures now performed.
Inclusion criteria for randomised controlled trials produce the po-
tential problem of reducing the applicability of the results to the
overall patient population. This was especially a problem in older
trials, which included stable or long-distance claudicants, who are
generally not offered surgery in contemporary practice. A sub-
component of any trial including such patients will therefore not
be applicable to the overall patient population, but should have
a minimal effect on the overall results as these trials have smaller
numbers than the more recent included trials. The included trials
are largely reflective of modern surgical practice in the UK and are
therefore relevant.
Data on limb salvage and survival with limb intact were gener-
ally not included for analysis in trials. In the future this should
be included as it is an important outcome, both for the patient
and from a health economics point of view (Luther 1997; Perler
1995), and may therefore influence practice significantly. Quality-
of-life data would also be useful in influencing treatment strategy
(Nolan 2007). This information might augment the applicability
of bypass surgery in general, as evidence is still lacking when com-
paring infrainguinal bypass with other treatments for lower limb
ischaemia (Fowkes 2008).
Human umbilical vein (HUV) has primary patency results com-
parable with other non-vein graft types, and may show an im-
provement in primary and secondary patency compared to poly-
tetrafluoroethylene (PTFE) below the knee. However, in one trial
up to 30% of HUV grafts showed graft dilation and aneurysm
formation (Aalders 1992). This, in combination with other data
at the time, has led to the diminished popularity of HUV in recent
years. More recent reviews did not find these factors to be a sig-
nificant issue (Dardik 2002) and the patency data from this meta-
analysis infer that HUV may be a suitable alternative to synthetic
materials when no autologous vein is available.
Heparin bonded Dacron is showing promising early results in ran-
domised trials (Devine 2004). Heparin bonded PTFE is also being
widely utilised in contemporary practice. While there are case se-
ries data implying that this is an effectivematerial, we could not in-
clude data from randomised trials in this review because the results
are either awaited (see tableCharacteristics of ongoing studies), un-
available due to the trial being terminated early (NCT00617279),
or reported in a way that does not separate above- and below-knee
results (Lindholt 2011).
A single small trial examined the use of polyurethane (PUR) grafts
(Gloor 1996). The trial was stopped early due to astonishingly
poor primary and secondary patency rates in the limbs treatedwith
the new graft material, so this material cannot be recommended.
Several specific problems could not be assessed in this analysis.
Firstly, infection of synthetic bypasses has disastrous consequences
for the patient (Siracuse 2013), whereas infection of venous by-
passes tends not to, and is easier to treat (Reifsnyder 1992). Oc-
clusion of synthetic bypasses appears to lead to limb loss more fre-
quently than venous (Jackson 2000), which is why it is so impor-
tant that future trials measure limb survival. A second limitation
of this review is the lack of information on antiplatelet and antico-
agulant protocols in the included studies; this may have produced
bias in the results and their interpretation. Finally, the majority
of included studies were not stratified according to graft length,
inflow site quality or inflow procedures, or patency of runoff ves-
sels.While the randomisation of participants should have achieved
balance with respect to these factors, the small numbers of partic-
ipants could potentially have led to imbalance between treatment
arms, in turn leading to biased results.
Quality of the evidence
While there were low numbers of trials for some comparisons,
these trials are mainly of reasonable methodological quality with
acceptable allocation concealment techniques, though often sim-
ple sealed envelopes were used and little-if any-effort appeared to
have been made to blind participants, practitioners or outcome
assessors (Figure 2; Figure 3). As a result, we assessed the major-
ity of the evidence contributing to above-knee bypass compar-
isons as low quality, which rose to moderate quality for one out-
come. We assessed the quality of the evidence on below-knee by-
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pass comparisons as very low-quality. Further details are included
in Summary of findings for the main comparison, Summary of
findings 2, Summary of findings 3 and Summary of findings 4.
All trials included a Kaplan-Meier analysis, and most supple-
mented thiswith numbers-at-risk and life table analyses. The num-
bers of participants at each stage of the trial were usually clear.
However, antiplatelet protocols were generally lacking. There is
clear evidence for antiplatelet therapy in cardiovascular stenting
(NICE 2003), which may be applicable to lower-limb arterial
stents (Twine 2009).While the evidence is less clear for lower-limb
bypass grafts (Brown 2008; Dorffler-Melly 2003); clear protocols
should be set in future trials to avoid the potential bias caused
by individual preferences by surgeons or centres for particular an-
tiplatelets or anticoagulants. Choice of anticoagulant for lower-
limb bypass grafts requires good-quality randomised controlled
trials to determine efficacy.
Potential biases in the review process
Although we are confident that a thorough search was carried out
for all relevant studies, we were unable to separate data from trials
from patients of below- and above-the-knee bypasses in all cases.
It has been clear for some time that below-knee bypass grafts have
significantly inferior patency rates to above-knee grafts (Cranley
1982; McCollum 1991). Most trials since the early 1990s have
therefore separated the two types of bypass for reporting results,
to avoid bias. This led to the division of above- and below-knee
procedures in this review. Three trials which were included in
previous editions of the reviewhave been excluded in this update or
previous updates (or both) as the above- and below-knee data were
inseparable (McCollum 1991;Moody 1992;Watelet 1997).More
recent trials with combined above- and below-knee procedures had
other severe methodological flaws which, in combination, led us
to exclude them (Robinson 1999; Robinson 2003). In addition,
we excluded two more recent trials either because of combined
above- and below-knee numbers (Lindholt 2011), or combined
below-knee and distal bypass numbers (Lundgren 2013). See the
table Characteristics of excluded studies.
Agreements and disagreements with other
studies or reviews
There are several recent meta-analyses of graft type for femoro-
popliteal bypass grafts (Albers 2005; Pereira 2006; Roll 2008;
Rychlik 2014a). In Albers 2005, alternative autologous vein (de-
fined as any autologous venous conduit other than a single section
of great saphenous vein) was compared with PTFE, HUV and
cryopreserved vein. Randomised controlled trials and cohort con-
trolled trials were considered for inclusion. The authors included
retrospective data and combined above- and below-knee bypasses.
Thirty-two articles with 2618 patients from studies conducted be-
tween 1982 and 2004 were included. Pooled estimate analysis was
performed in which the authors found no difference in primary
patency between autologous vein and PTFE, but reported a signif-
icant improvement in secondary patency and foot preservation for
alternative autologous veins. While not directly comparable with
our analysis, these data provide more evidence for autologous vein
over prosthetic grafts.
In Pereira 2006, above-knee autologous vein, PTFE and below-
knee autologous vein were compared. Randomised controlled tri-
als and cohort trials were considered for inclusion. Forty-nine ret-
rospective articles and 24 prospective articles from 1986 to 2004
were included. As well as including retrospective data, the authors
included several studies which we excluded from our analysis be-
cause of inadequate randomisation. Pooled estimate analysis was
performed, in which the authors found a significant improvement
in primary patency for above-knee autologous vein when com-
pared with PTFE. Secondary patency was lower for all graft types
and showed no significant difference. Therefore, Pereira 2006 also
broadly agrees with the findings of this analysis that autologous
vein performs better than PTFE above the knee. The authors’
findings should, however, be interpreted with caution due to the
nature of the data included.
One meta-analysis (Roll 2008), compared Dacron with PTFE
and found no difference between the graft types. The authors
included bypasses other than femoro-popliteal (axillo-bifemoral,
aorto-bifemoral, etc.) but had strict inclusion criteria and therefore
included good-quality trials. Our analysis is in broad agreement
with the findings of Roll 2008 in terms of primary patency, though
we did find an improvement in secondary patency at 24 months
and five years, the latter as a result of data from the van Det study
(van Det 2009), published after Roll (Roll 2008). Therefore, the
findings of our analysis are broadly in agreement with Roll 2008.
For this reason, the long-term secondary patency benefit towards
Dacon is tentative, as discussed throughout the text.
One meta-analysis (Rychlik 2014a) compared Dacron with PTFE
above the knee.It had similar exclusion criteria to our review and
found results from five studies which are included in our analysis,
in addition to one studywhichwe excluded fromourmeta-analysis
due to its methodological flaws (Davidovic 2010). They chose
to include the results of Devine 2004, which compared heparin
bonded Dacron with PTFE, alongside the four studies comparing
standard Dacron with PTFE (Abbot 1997; Jensen 2007; Post
2001; vanDet 2009). Their conclusions were similar to our results
in this context: that Dacron has superior patency to PTFE at 2
and 5 years follow-up.
A previous meta-analysis (Twine 2012) has shown benefit for
PTFE with vein cuff for below-knee bypass. This analysis included
non-randomised studies, and based on the results seen in our anal-
ysis, the benefit shown in Twine 2012 may be because of selec-
tion bias in the non-randomised data. It is unlikely that another
RCT of cuffed bypass will be performed, and most surgeons will
perform a cuffed anastomosis for synthetic bypass distal to the
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knee. Registry data is becoming increasingly prevalent in vascular
surgery and may help to answer this question more definitively in
the future.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found moderate-quality evidence that autologous vein grafts
improve long-term (60 months) primary patency over prosthetic
graft materials for femoro-popliteal bypass above the knee. There
was low-quality evidence that Dacron grafts had improved long-
term (two to five years) secondary patency compared to polyte-
trafluoroethylene (PTFE) above the knee. External reinforcement
of Dacron grafts had inferior primary patency above the knee. Hu-
man umbilical cord (HUV) and heparin bonded Dacron (HBD)
may also have superior patency to PTFE, but the results are from
only one trial in each case. There was no evidence to support any
one synthetic material for bypasses below the knee. Further ran-
domised data are needed to ascertain whether this information
translates into an improvement in limb survival.
Implications for research
Randomised trials of synthetic materials versus autologous vein
and other prosthetic materials are ongoing (NCT00205790;
NCT00147979). While data on new graft types are invaluable,
further randomised data are needed on ’established’ materials used
for femoro-popliteal bypasses. This especially includes the use of
vein cuffs with different prosthetic materials below the knee. Ran-
domised trials of HBD versus Dacron would also be useful, as
would randomised data comparing ’alternative’ autologous vein
(for example profunda femoris, arm vein and ’inadequate’ saphe-
nous vein) with prosthetic materials.
Future trials need to include data on limb survival, quality of life
and costs, as well as patency rates, to ascertain whether the im-
provements in patency found in this analysis translate into im-
provements in these important outcomes. It would also be helpful
if infection rates could be reported in future trials, though the low
event rates seen in observational studies of graft infection would
suggest that studies looking at this issue might need to be very
large.
While vein cuffs or pre-cuffed grafts are widely utilised below the
knee, this practice is based on case-series data. This would be
a useful topic to study in future trials, since vein is not always
available and the results of randomised studies of this technique
are conflicting.
The effects of antiplatelets or anticoagulants on graft patency also
need to be investigated further in the context of randomised con-
trolled trials. This would facilitate graft-type trial medication pro-
tocols and remove a major potential source of bias from future
studies.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aalders 1992
Methods Site: Femoral to AK popliteal
Study design: Single-centre RCT
Method of randomisation: sealed envelopes
Blinding: unblinded, intention to treat
Exclusions post randomisation: none
Losses to follow up: none
Participants Country: Holland
No. of participants: 85 patients(93 limbs; 46 PTFE, 47 HUV)
Age: 64 yrs
Sex: 67 male, 18 female
DM 16, critical 17
Inclusion criteria: AK femoro-popliteal graft for IC (or limb salvage if vein unavailable)
Exclusion criteria: those with previous femoro-popliteal graft
Interventions 6 mm PTFE versus 6 mm HUV
Outcomes Primary patency, secondary patency, complications
Notes All had post-op anticoagulants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Random permuted blocks”
Allocation concealment (selection bias) Unclear risk Not specifically stated. Probably not done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Operative blinding impossible in this type
of trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors and patients not obvi-
ously blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Some patients lost to follow-up early on,
but clear life table data
Selective reporting (reporting bias) Low risk All stated outcomes reported
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Other bias Low risk No other obvious bias
Abbot 1997
Methods Site: Femoral to AK popliteal
Study design: Multicentre RCT
Method of randomisation: central randomisation, but exact method unclear
Blinding: unblinded, intention to treat
Exclusions post randomisation: not discussed
Losses to follow up: high rate of losses to follow-up (37 within first 12 months of follow-
up)
Participants Country: USA
Setting: multicentre
No. of participants: 231 patients (240 limbs; 122 PTFE, 118 Dacron)
Age: mean 67.1 yrs
Sex: 145 male, 95 female
Inclusion criteria: angiographically demonstrated superficial femoral artery occlusion
with reconstitution of a popliteal segment above the knee
Exclusion criteria: earlier infrainguinal vascular procedures
Unclear whether patients had IC or critical ischaemia
Interventions PTFE versus Dacron (diameter at discretion of operating surgeon)
Outcomes Primary patency, secondary patency, peri-operative complications
Notes 13 patients randomised but not described. Unclear how many patients had post-op
aspirin
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomised cen-
trally after eligibility was determined by the
operating surgeon and informed consent
obtained.”
Allocation concealment (selection bias) Unclear risk Not specifically stated. Probably not done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Operative blinding impossible in this type
of trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors and patients not obvi-
ously blinded
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Incomplete outcome data (attrition bias)
All outcomes
High risk 37 patients randomised lost by 12 months
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Unclear risk Anticoagulation protocol not stated
Ballotta 2003
Methods Site: Femoral to AK popliteal
Study design: RCT
Method of randomisation: concealed randomisation using computer generated randomi-
sation envelopes
Blinding: unblinded, intention to treat
Exclusions post randomisation: none
Losses to follow up: none
Participants Country: Italy
Setting: hospital
No. of participants: 51 (102 limbs; 51 PTFE, 51 reversed vein)
Age (mean): 62 yrs
Sex: 33 males, 18 females
Inclusion criteria: severe claudication, SFA occlusion with one to three runoff vessels
Exclusion criteria: untreated inflow disease of ipsilateral pelvic arteries (more than 50%
stenosis or occlusion); previous bypass procedure or stent in target SFA; multiple lesions
exceeding 10 cm; acute critical limb ischaemia; an untreated ipsilateral iliac artery steno-
sis; known intolerance to study medications or contrast agents
Interventions 8 mm PTFE and reversed vein graft
Oral warfarin from one day pre-op and continued for 6 months; 325 mg aspirin after-
wards
Outcomes Primary assisted patency as remedial surgery for late bypass stenosis was not considered
a primary failure
5-year data
Notes Compliance with medication not checked
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Concealed randomisation using
computer generated randomisation en-
velopes.”
Allocation concealment (selection bias) Low risk Envelopes sealed as above
32Graft type for femoro-popliteal bypass surgery (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ballotta 2003 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Operative blinding impossible in this type
of trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors and patients not obvi-
ously blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No patients lost to long term follow up
(mean 59 months)
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No other obvious bias
Davidovic 2010
Methods Site: Femoral to AK popliteal
Study design: RCT
Method of randomisation: not described
Blinding: unblinded, intention to treat
Exclusions post randomisation: none
Losses to follow up: not specified
Participants Country: Serbia
Setting: hospital
No. of participants: 85 (43 ePTFE, 42 Dacron)
Age (mean): 65.5 yrs
Sex: 71 males, 14 females
Inclusion criteria: severe claudication or critical ischaemia, “considered suitable for sur-
gical revascularization using above-knee prosthetic bypass graft”
Exclusion criteria: previous procedures on aorto-iliac or ipsilateral femoro-politeal arterial
segments
Interventions 8 mm FlowNit Biosel (Dacron) or 8mm FlowLine BioPore (ePTFE) bypass graft from
femoral to above-knee popliteal artery. All patients given 4 days’ antibiotic prophylaxis
with a second generation cephalosporine and started on acetylsalicylic acid immediately
after surgery
Outcomes Primary: primary patency, early complications (mortality, bleeding and infection), early
limb salvage
Secondary: secondary patency, mid-term complications (mortality, false anastomotic
aneurysms and infection), mid-term limb salvage
Notes Clear antibiotic and antiplatelet protocols
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not specified
Allocation concealment (selection bias) Unclear risk Allocation concealment not discussed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Operative blinding impossible in this type
of trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors and patients not obvi-
ously blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Numbers at risk not presented with sur-
vival curves, secondary patency presented
as worse than primary patency, which is im-
possible
Selective reporting (reporting bias) Low risk All outcomes presented, but numbers at
risk at different time points not given so
impossible to discern significance of differ-
ent rates
Other bias Low risk Clear antiplatelet and antibiotic protocols
Devine 2004
Methods Site: Femoral to AK and BK popliteal
Study design: RCT
Method of randomisation: concealed randomisation using computer generated randomi-
sation envelopes
Blinding: unblinded, intention to treat
Exclusions post randomisation: none
Losses to follow up: none
Participants Country: UK
Setting: hospital
No. of participants: 209 (AK: 88 PTFE, 91 HBD; BK: 15 PTFE, 15 HBD)
Age (mean): 63 yrs
Sex: 142 males, 67 females
Inclusion criteria: severe claudication, SFA occlusion with one to three runoff vessels
Exclusion criteria: emergency surgery for trauma, acute thrombosis, embolism, or
popliteal artery thrombosis
Symptoms not sufficiently severe to disrupt lifestyle or ABI > 0.8 at rest (unless aneurysm)
, the diagnosis or treatment for malignancy within 12 months including all cases with
residual malignancy being followed up or observed, hospital inpatient treatment for
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cardiac failure in the previous 6 months, where adequate follow-up would be impossible
to arrange because the patient lived or was moving to an area where independent follow
up could not be arranged
Interventions HBD or PTFE (diameter at discretion of operating surgeon)
Anticoagulation not stated
Outcomes Primary patency
Notes Anticoagulation not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization, stratified for AK
or BK and by surgeon, was performed for
eligible patients, using a dedicated com-
puter program.”
Allocation concealment (selection bias) Low risk Quote: “Sealed randomization envelopes
(1 for AK, 1 for BK) were delivered to the
vascular surgeon before surgery.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Operative blinding impossible in this type
of trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors and patients not obvi-
ously blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No losses, but numbers at risk not given for
below knee outcomes so attrition not clear
for this outcome
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Unclear risk Anticoagulation protocol not stated
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Methods Site: Femoral to BK popliteal
Study design: multicentre RCT
Method of randomisation: sealed envelopes
Blinding: unblinded, intention to treat
Exclusions post randomisation: none
Losses to follow up: none
Participants Country: Scandinavia
Setting: hospital
No. of participants: 105 (55 PTFE, 50 HUV)
Age: 68 yrs
Sex: 60 male, 45 female
Inclusion criteria: DM 12, critical ischaemia 80. BK fem-pop for short distance IC or
critical ischaemia, if no vein or CABG intended
Exclusion criteria: short life expectancy, previous graft, Buerger’s, coagulopathy
Interventions PTFE versus HUV (diameter at discretion of operating surgeon)
Outcomes Secondary patency
Notes Post-op anti-thrombotic/coagulant therapy unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear as to how the randomisation se-
quence was generated
Allocation concealment (selection bias) Low risk Sealed envelopes used
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Operative blinding impossible in this type
of trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors and patients not obvi-
ously blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses, clear life table data
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Unclear risk Anticoagulation protocol not stated
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Gloor 1996
Methods Site: Ilio or femoral to AK popliteal
Study design: single-centre RCT
Method of randomisation: not explicitly stated
Blinding: stated to be single-blind
Exclusions post randomisation: not stated
Losses to follow up: none
Protocol violations: none stated
Participants Country: France
Setting: hospital
No. of participants: 18 (20 limbs; 10 PUR graft, 10 Dacron)
Age (mean): PUR group: 70.7 years; Dacron: 70.5 years
Sex: Overall 13 men, 7 women; PUR group: 6 men, 4 women; Dacron group: 7 men,
3 women
Inclusion criteria: peripheral arterial occlusion of lower limb graded Fontaine stage IIb-
IV requiring AK synthetic ilio- or femoro-popliteal bypass
Exclusion criteria: obesity, emergency surgery, critical threat to limb
Interventions Iliac or Femoral to AK popliteal bypass graft with either 6 mm PUR or 6 mm Dacron
Outcomes Primary and secondary patency, complications in first 30 days, reintervention rate
Notes Clear anticoagulation/antiplatelet protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not stated
Allocation concealment (selection bias) Unclear risk Timing of randomisation not declared
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Operative blinding impossible in this type
of trial, though participants were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors not obviously blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No PRISMA flow chart, no mention of pa-
tients excluded prior to randomisation or
after randomisation
Selective reporting (reporting bias) Unclear risk Primary and secondary patency as well as
reinterventions reported, but no complica-
tions in first 30 days which did not lead to
reintervention mentioned
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Other bias Low risk Clear anticoagulation and antiplatelet pro-
tocol
Gupta 1991
Methods Site: Femoral to AK or BK popliteal
Study design: single-centre RCT
Method of randomisation: selecting a random card from an unsorted deck of cards
marked with the choice of graft material
Blinding: unblinded, no documented crossover so as treated/intention to treat analysis
not discussed
Exclusions post randomisation: none
Losses to follow up: none
Protocol violations: none
Participants Country: USA
Setting: hospital
No. of participants: 122 (59 AK of whom 29 ringed, 63 BK of whom 29 ringed)
Age (mean): 71 yrs
Sex: split not specified
Inclusion criteria: patients without an available ipsilateral ASV long enough to serve as
femoro-popliteal bypass on the basis of a history of prior removal, duplex ultrasonog-
raphy, saphenous venography or operative findings requiring an AK or BK femoro-
popliteal bypass. Patients whose life expectancy was judged to be less than 3 years were
also included whether or not an ipsilateral ASV was available
Patients with Rutherford category 1 to 5 ischaemia were eligible, though all but 4 patients
had rest pain or tissue loss
Exclusion criteria: patients with extensive necrosis requiring sequential grafts to distal
arteries, patients requiring bypass for reasons other than arteriosclerotic occlusive disease
Interventions 6 mm ringed or unringed PTFE
Outcomes Primary patency, secondary patency, limb salvage (secondary patency and limb salvage
not presented separately for above and below-knee grafts so not included)
Notes Clear anticoagulation and antiplatelet protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation by selection of “a random
card fromanunsorted deck of cardsmarked
with the choice of graft material”
Allocation concealment (selection bias) Unclear risk Timing of randomisation not declared
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Operative blinding impossible in this type
of trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors and patients not obvi-
ously blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses, clear life table data
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk Clear anticoagulation and antiplatelet pro-
tocol
Jensen 2007
Methods Site: Femoral to AK popliteal (POPUP study)
Study design: RCT
Method of randomisation: randomisation envelopes
Blinding: unblinded, intention to treat
Exclusions post randomisation: 13 (8 Dacron, 5 PTFE)
Losses to follow up: 51 (12%)
Participants Country: Scandinavia
Setting: hospital (13 departments)
No. of participants: 426 (413 for analysis due to exclusions; 205 PTFE, 208 Dacron)
Age (mean): 66 yrs
Sex: 152 males, 261 females
Inclusion criteria: “chronic lower limb ischaemia”
Exclusion criteria: less than 18, pregnant, could not obtain informed consent
Interventions 6 mm PTFE and 6 mm Dacron graft
Anticoagulation as per individual centre protocol
Outcomes Primary patency, secondary patency and limb survival
Notes No common anticoagulation pathway. Multiple, different surgeons
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Grafts were contained in envelopes, how-
ever the randomisation procedure is un-
clear. Probably done as other papers from
this unit clearly use random sequences
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(Eiberg 2006; Vogt 2007)
Allocation concealment (selection bias) Low risk Quote: “Immediately before surgery, the
graft material was selected by a pre-pro-
cessed sealed envelope. Randomisation was
stratified for each centre.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Operative blinding impossible in this type
of trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors and patients not obvi-
ously blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses, clear life table data
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Unclear risk Anticoagulation as per individual centre
protocol and therefore inconsistent
Klinkert 2003
Methods Site: Femoral to AK popliteal
Study design: RCT
Method of randomisation: concealed randomisation using computer generated randomi-
sation envelopes
Blinding: unblinded, intention to treat
Exclusions post randomisation: none
Losses to follow up: 11 (7%)
Participants Country: the Netherlands
Setting: hospital
No. of participants: 136 (151 limbs; 75 Saphenous vein, 76 PTFE)
Age (median): 69 yrs
Gender: 88 males, 48 females
Inclusion criteria: severe claudication, rest pain, tissue loss
Exclusion criteria: patients with earlier bypass or previously removed long saphenous
vein
Interventions 6 mm PTFE and reversed vein graft
Oral warfarin from one day pre-op continued for 6 months. 38 mg aspirin afterwards
Outcomes Primary and secondary patency
5-year follow up
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Notes No compliance checks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear. No specific description
Allocation concealment (selection bias) Low risk Quote: “randomization took place with
closed envelope allocation.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Operative blinding impossible in this type
of trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors and patients not obvi-
ously blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 13 patients lost to long term follow up,
clearly described
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk Oral warfarin from one day pre-op contin-
ued for 6 months. 38mg aspirin afterwards
Lumsden 2015
Methods Site: Femoral to AK or BK popliteal
Study design: multicentre RCT
Method of randomisation: not stated
Blinding: unblinded, as treated analysis
Exclusions post randomisation: 3 (1.4%)
Losses to follow up: 4 (1.9%)
Protocol violations: 1 (treatment with a non test graft)
Participants Country: 18 centres in the USA and 7 in Europe
Setting: hospital
No. of participants: 209 (105 FUSION BIOLINE, 101 standard ePTFE, 2 no graft
implanted, 1 non test graft implanted so latter 3 excluded)
Age (median): 62 yrs in standard ePTFE group, 67 in FUSION BIOLINE group
Sex: 145 males, 58 females; 2 excluded
Inclusion criteria: patients requiring an AK or BK femoro-popliteal bypass with the
proximal anastomosis at the level of the distal external iliac, common femoral, profunda
femoral, or proximal superficial femoral artery. The study protocol specified that a pros-
thetic femoro-popliteal bypass must be medically necessary, but did not, per se, exclude
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those without an adequate autogenous conduit. Patients with Rutherford category 1 to
5 ischaemia were eligible, with symptoms of claudication, rest pain, or with superficial
ulceration in the target lower extremity
Exclusion criteria: acute arterial occlusion requiring urgent intervention; prior open
surgical bypass in the target extremity; angioplasty or stenting at the site of a planned
anastomosis within the previous 30 days; serum creatinine > 2.5 mg/dL; recent (< 6
weeks)MI or stroke; coagulation or bleeding disorders; receiving warfarin therapy where
oral anticoagulation could not be withheld
Interventions FUSION BIOLINE heparin coated vascular graft or standard ePTFE graft (diameter at
discretion of operating surgeon)
Outcomes Primary endpoints: efficacy: primary graft patency at 6 months as assessed by duplex ul-
trasound imaging and ABI. Safety: the composite of MALE and POD. MALE included
major amputation, major graft reintervention with placement of a new graft or an inter-
position graft, open or percutaneous graft thrombectomy, pharmacologic thrombolysis,
or graft excision. POD was defined as those that occurred within 30 days of the index
procedure or any remedial procedure performed at the same anatomic site. Secondary
endpoints: efficacy: primary assisted patency, secondary patency, and bleeding at the
suture hole as judged subjectively by the operating surgeon and objectively by recording
the time between restoration of flow into the graft and the absence of detectable bleeding
from the suture holes
Notes No consistent anticoagulation protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description of randomisation sequence
generation technique
Allocation concealment (selection bias) Unclear risk Timing and method of randomisation al-
location not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Operative blinding impossible in this type
of trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors and patients not obvi-
ously blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 4 patients had missing data at 6-
month follow-up
Selective reporting (reporting bias) Low risk All stated outcomes reported
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Other bias Unclear risk No consistent anticoagulation protocol
Post 2001
Methods Site: Femoral to AK and BK popliteal
Study design: RCT
Method of randomisation: concealed randomisation using computer generated randomi-
sation envelopes
Blinding: unblinded, intention to treat
Exclusions post randomisation: 3 (1%)
Losses to follow up: 6 (2%)
Participants Country: Germany
Setting: hospital
No. of participants: 203 (194 limbs analysed. AK: 65 PTFE, 76 Dacron, BK: 26 PTFE,
27 Dacron)
Age (median): 66 yrs
Sex: 155 males, 48 females
Inclusion criteria: severe claudication, rest pain, tissue loss
Exclusion criteria: infection, emergency surgery for acute ischaemia, distal anastomosis
below anterior tibial origin, concomitant disease not expected to live past 3 years, con-
traindication to anticoagulants
Interventions PTFE and Dacron (diameter at discretion of operating surgeon)
Post-op warfarin, heparin or antiplatelet agents
Outcomes Primary patency
3-year follow up
Notes No consistent anticoagulation protocol. No compliance checks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The order of Secondary end-
points assignment had been generated by
random digits from a statistical software
package (SAS).”
Allocation concealment (selection bias) Low risk Quote: “Patients were randomised to either
treatment arm intraoperatively by sealed
envelopes.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Operative blinding impossible in this type
of trial
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors and patients not obvi-
ously blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses, clear life table data
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Unclear risk No consistent anticoagulation protocol
SCAMICOS 2010
Methods Site: BK popliteal and distal (the latter not included in this review)
Study design: multicentre RCT
Method of randomisation: concealed randomisation using sealed envelopes in blocks of
16 per centre
Blinding: unblinded, intention to treat
Exclusions post randomisation: 3 (1%)
Losses to follow up: 0 (0%)
Protocol violations: 3 (1 - suitable vein available, 1 - distal reconstruction below popliteal
artery, 1 - crossover from non-collar to collar group)
Participants Country: 29 centres in Sweden and 3 in Denmark
Setting: hospital
No. of participants: 202 (87 PTFE, 115 PTFE with vein collar)
Age (median): 79 yrs in PTFE group, 76 yrs in PTFE with collar group
Gender: 77 males, 122 females; 3 excluded
Inclusion criteria: rest pain, tissue loss
Exclusion criteria: no suitable distal anastomotic target, distal anastomosis AK or below
anterior tibial origin for BK popliteal group, or below-ankle for distal group
Interventions Gore or Impra PTFE graft with or without distal vein cuff, diameter not specified
(diameter at discretion of operating surgeon)
Outcomes Primary patency; secondary patency; amputation; death
Notes No consistent anticoagulation protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description of randomisation sequence
generation technique
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Allocation concealment (selection bias) Low risk Envelope selected at random after confir-
mation of suitable target vessel
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Operative blinding impossible in this type
of trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors and patients not obvi-
ously blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 3 patients hadmissing follow-up data
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Unclear risk No consistent anticoagulation protocol
Scharn 2008
Methods Site: AK
Study design: RCT
Method of randomisation: controlled by the BOA-trial agency using a dedicated com-
puter program
Blinding: unblinded, intention to treat
Exclusions post randomisation: 8 (6%)
Losses to follow up: 13 (9%)
Participants Country: the Netherlands
Setting: hospital
No. of participants: 137 (137 limbs with 8 excluded; 59 HBD, 70 HUV)
Age (median): 65 yrs
Sex: 87 males, 50 females
Inclusion criteria: severe claudication, rest pain, tissue loss
Exclusion criteria: patients younger than 30 or older than 90 yrs of age; patients with an
ABI higher than 0.8 at rest, emergency surgery for trauma, acute thrombosis or embolism
of the popliteal artery, the diagnosis or treatment for malignancy within 12 months,
hospital in-patient treatment for cardiac failure in the previous 6 months, the absence
of the possibility for adequate follow up or contraindications for anticoagulant drug
therapy
Interventions Heparin bonded Dacron and HUV (diameter at discretion of operating surgeon)
Aspirin 80 mg daily or coumarin derivates (Sintrom)
Outcomes Primary patency. 5-year follow-up
Notes No consistent anticoagulation protocol. No compliance checks
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was controlled by
the BOA-trial agency using a dedicated
computer program.”
Allocation concealment (selection bias) Low risk Not specifically stated but assumed done as
BOA-trial agency involved
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Operative blinding impossible in this type
of trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors and patients not obvi-
ously blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses, clear life table data
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Unclear risk No consistent anticoagulation protocol
Solakovic 2008
Methods Site: AK popliteal
Study design: single-centre RCT
Method of randomisation: concealed randomisation using sealed envelopes following
intraoperative assessment of artery and vein
Blinding: unblinded, intention to treat
Exclusions post randomisation: none
Losses to follow up: 9 (7%)
Protocol violations: none
Participants Country: 1 centre in Bosnia
Setting: hospital
No. of participants: 109 patients, 121 limbs (12 patients had a second bypass in the
contralateral limb during the study period). There were 60 reversed LSV bypasses and
61 prosthetic bypasses (PTFE or Dacron, material not further specified)
Age (median): 70 yrs in reversed LSV group, 68 in prosthetic group
Sex: 70 males, 51 females
Inclusion criteria: rest pain, tissue loss, ’disabling claudication’
Exclusion criteria: previous revascularisation in treated leg, LSV not available or suitable,
CFA or AK popliteal not suitable site for anastomosis
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Interventions Reversed LSV or 6 mm prosthetic bypass from CFA to above-knee popliteal artery
Outcomes Primary patency, secondary patency
Notes All patients received prophylactic clexane at a dose of 0.5 ml/kg while in hospital and
then 150mg/day aspirin after discharge. Compliance with this protocol was not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description of randomisation sequence
generation technique
Allocation concealment (selection bias) Low risk Envelope selected at random after confir-
mation of suitable target vessel and suitable
vein
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Operative blinding impossible in this type
of trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors and patients not obvi-
ously blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 7% of patients lost to follow-up over
5 years
Selective reporting (reporting bias) Low risk Stated outcomes reported
Other bias Unclear risk Consistent anticoagulationprotocol but no
compliance checks reported
Stonebridge 1997
Methods Site: Femoral to AK or BK popliteal
Study design: multicentre RCT
Method of randomisation: central randomisation centre assessment of artery and vein
Blinding: unblinded, intention to treat
Exclusions post randomisation: not specified
Losses to follow up: not stated
Protocol violations: none declared
Participants Country: UK
Setting: multicentre
No. of participants: 246
Inclusion criteria: femoro-popliteal graft to AK (76 cuff, 74 no cuff ) or BK (48 cuff, 47
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no cuff ) popliteal
Exclusion criteria: trauma
Interventions 6 mm PTFE with and without a vein cuff
Outcomes Primary patency, secondary patency, limb salvage
Notes No consistent anticoagulation protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Nodescriptionof randomisation technique
Allocation concealment (selection bias) Unclear risk No clear description
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Operative blinding impossible in this type
of trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors and patients not obvi-
ously blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Attrition rates not clearly presented
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Unclear risk No consistent anticoagulation protocol
Tofigh 2007
Methods Site: AK
Study design: RCT
Method of randomisation: unclear
Blinding: unblinded, intention to treat
Exclusions post randomisation: none
Losses to follow up: 6 (6%)
Participants Country: France
Setting: hospital
No. of participants: 85 (103 limbs; 51 reversed vein, 52 polyester)
Age (median): 69 yrs
Sex: 49 males, 36 females
Inclusion criteria: severe claudication, rest pain, tissue loss
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Tofigh 2007 (Continued)
Exclusion criteria: patients with earlier bypass or un-useable LSV
Interventions 6 mm collagen-impregnated woven polyester prosthesis and reversed vein graft
Oral warfarin from one day pre-op continued for 6 months. 38 mg aspirin afterwards
Outcomes Primary and secondary patency
5-year follow-up
Notes No medication compliance checks. Unclear randomisation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Nodescriptionof randomisation technique
Allocation concealment (selection bias) Unclear risk No clear description
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Operative blinding impossible in this type
of trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors and patients not obvi-
ously blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses, clear data
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk No obvious other source of bias
van Det 2009
Methods Site: AK
Study design: RCT
Method of randomisation: sealed envelopes
Blinding: unblinded, intention to treat
Exclusions post randomisation: none
Losses to follow up: 4 (%)
Participants Country: France
Setting: hospital
No. of participants: 228 (228 limbs; 114 Dacron, 114 PTFE)
Age (median): 66 yrs
Sex: 147 males, 81 females
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van Det 2009 (Continued)
Inclusion criteria: severe claudication, rest pain, tissue loss
Exclusion criteria: patients with earlier bypass contraindication to long term anticoagu-
lant therapy, life expectancy less than 1 year
Interventions 6 mm PTFE or 6 mm Dacron. Warfarin post-op (all patients)
Outcomes Primary, primary assisted and secondary patency
10-year follow-up
Notes Good anticoagulation protocol. Clear numbers of patients throughout (flow chart)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer program used for sequence gen-
eration
Allocation concealment (selection bias) Low risk Sealed envelopes used
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Operative blinding impossible in this type
of trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors and patients not obvi-
ously blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses, clear life table data
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk Good anticoagulation protocol. Clear
numbers of patients throughout (flow
chart)
50Graft type for femoro-popliteal bypass surgery (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Vriens 2013
Methods Site: Femoral to AK popliteal
Study design: multicentre RCT
Method of randomisation: concealed randomisation using sealed envelopes in blocks of
4 per centre
Blinding: unblinded, as treated analysis
Exclusions post randomisation: 1 (0.4%)
Losses to follow up: 4 (1.5%)
Protocol violations: 1 (1 - crossover from allocated group)
Participants Country: 6 centres in the Netherlands
Setting: hospital
No. of participants: 266 (136 externally supported polyester, 129 non-externally sup-
ported polyester, 1 not treated according to protocol so excluded)
Age (median): 65 yrs in externally supported group, 67 in non externally supported
group
Sex: 199 males, 66 females; 1 excluded
Inclusion criteria: all patients requiring AK femoro-popliteal bypass for disabling clau-
dication, rest pain, tissue loss in the absence of a suitable venous conduit
Exclusion criteria: no suitable distal anastomotic target, distal anastomosis not above
knee, previous ipsilateral femoro-popliteal procedures, contra-indication for the use of
acetyl salicylic acid or anticoagulants, patients receiving chemo- or radiotherapy, ma-
lignancy diagnosed or treated within 12 months, known allergy to iodine or contrast
medium, and impaired renal function
Interventions Fluoropassiv 6mmknitted polyester, either externally supported thin-wall fluoropolymer
coated or 6 mm externally unsupported thin wall
Outcomes Primary endpoints: primary patency at 1 and 2 years post-op. Secondary endpoints:
mortality, primary assisted and secondary patency
Notes Clear anticoagulation protocol. Clear numbers of patients throughout (flow chart)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description of randomisation sequence
generation technique
Allocation concealment (selection bias) Low risk Envelope selected at random after confir-
mation of suitable target vessel
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Operative blinding impossible in this type
of trial
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Outcome assessors and patients not obvi-
ously blinded
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Vriens 2013 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 4 patients (1.5%) were lost to follow-
up
Selective reporting (reporting bias) Low risk All stated outcomes reported
Other bias Low risk Good anticoagulation protocol. Clear
numbers of patients throughout (flow
chart)
ABI: ankle brachial index
AK: above knee
ASV: autologous saphenous vein
BK: below knee
CABG: coronary bypass graft
CFA: common femoral artery
DM: diabetes mellitus
HBD: heparin bonded Dacron
HUV: human umbilical vein
IC: intermittent claudication
LSV: long saphenous vein
MALE: major adverse limb events
MI: myocardial infarction
POD: peri-procedural death
post-op: post-operative/operatively
pt: patient
PTFE: polytetrafluoroethylene
PUR: polyurethane
RCT: randomised controlled trial
SFA: superficial femoral artery
yrs: years
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bennion 1985 Results presented include non-randomised patients. Randomisation technique unclear. Distal grafts included,
not intention to treat
Chikiar 2003 Retrospective, non-randomised study (not an RCT or CCT): retrospective study where data were collected from
patient records
Erasmi 1996 The trial was performed in patients having femoro-popliteal bypass both above and below the knee. Outcomes
for the above- and below-knee subgroups were not reported so it was not possible to include the trial
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(Continued)
Hamann 1998 Randomisation technique unclear, above-knee, below-knee and distal bypasses inseparable (English title states
above-knee but methods talk about below-knee bypass)
Hobson 1980 Case series, not randomised trial data
Johnson 2000 Inadequate randomisation process. Quote: “the choice between a PTFE and HUV bypass graft was randomized
in the operating room, initially to favour saphenous vein.” The data were presented as vein versus HUV versus
PTFE and was inseparable for analysis
Kreienberg 2002 Bypass to any below-knee artery, not just popliteal. Randomisation technique unclear
Kumar 1995 Unclear randomisation process. Results never fully published in paper form, only as two abstracts. Data presented
as vein versus PTFE versus Dacron and were inseparable for analysis
Lindholt 2011 The trial was performed in patients having femoro-popliteal bypass both above and below the knee. Outcomes
for the above- and below-knee subgroups were not reported so it was not possible to include the trial
Linni 2015 The trial was performed in patients having femoro-popliteal and more distal bypass. Outcomes for the subgroups
of patients with distal anastomosis the above-knee popliteal or below-knee popliteal artery were not reported so
the study could not be included
Lundgren 2013 The trial was performed in both patients having femoro-popliteal bypass below the knee and patients having
femoro-distal bypass. Outcomes for the subgroup having femoro-popliteal bypass alone were not reported
McCollum 1991 Unable to separate above- and below-knee data
Midy 2016 Trial failed to recruit 30% of planned patients, and lost 26% of these to follow up. Results only presented at 5
years follow-up using an unusual system to impute missing data
Moody 1992 Unable to separate above- and below-knee data
Motta 1989 Above-knee, below-knee and distal bypasses inseparable; unclear randomisation
NCT00617279 Trial terminated by sponsor due to slow recruitment. No results available
NCT00845585 Trial withdrawn prior to enrolment of any patients
Robinson 1999 Unable to separate above- andbelow-knee data. A proportion of both above- andbelow-knee anastomoses included
endarterectomies and or vein cuffs which the study authors concede produced a significant difference in patency
without giving detailed subgroup analysis. Unclear randomisation
Robinson 2003 Unable to separate above- and below-knee data. Below-knee anastomotic site described as ’distal’ in some cases
without detailed anatomical description. A proportion of both above- and below-knee anastomoses included
endarterectomies and or vein cuffs which the study authors concede produced a significant difference in patency
without giving detailed subgroup analysis. Unclear randomisation
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(Continued)
Schulman 1987 Patients received both above- and below-knee bypass grafts but results presented together. Poor randomisation
(month of birth)
Tilanus 1985 Unable to separate above- and below-knee data. Unclear randomisation technique
Veith 1986 Unable to separate above- and below-knee data. Inadequate randomisation (hospital number, card pulling, random
number generator)
Watelet 1997 The trial was performed in patients having femoro-popliteal bypass both above and below the knee. Outcomes
for the above- and below-knee subgroups were not reported so it was not possible to include the trial
Zilla 1994 Unable to separate above- and below-knee data, not intention to treat. Inadequate randomisation (randomnumber
generator, concealment not stated)
CCT: clinically controlled trial
HUV: human umbilical vein
PTFE: polytetrafluoroethylene
RCT: randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
NCT00147979
Trial name or title Multicentric, Prospective, Randomized, Comparing Trial Between Bypass of the Femoropoplitea by PTFE
and Heparin Bounded PTFE
Methods Randomised controlled trial
Participants 18 years and older, peripheral vascular disease requiring above- or below-knee femoro-popliteal bypass
Interventions PTFE versus PTFE with bonded heparin
Outcomes Primary outcome measures: primary patency after 2 years
Secondary outcome measures: secondary patency; limb salvage; mortality; re-intervention
Starting date April 2004
Contact information Frank Vermassen, MD, PhD, University Hospital, Ghent
Notes A preliminary survival curve was presented at the Charing Cross Symposium in 2009. No useable data could
be gleaned from this and no official abstract was published. The lead author was contacted for results but did
not reply. The study is reported as completed on ClinicalTrials.gov but has not been published
ClinicalTrials.gov identifier: NCT00147979
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NCT00205790
Trial name or title GORE-TEX PROPATEN Vascular Graft Study
Methods Single-blind randomised controlled trial
Participants 21 years and older, peripheral vascular disease requiring above-knee femoro-popliteal bypass
Interventions GORE-TEX PROPATEN vascular grafts versus thin walled GORE-TEX Stretch vascular grafts
Outcomes Primary outcome measures: primary patency at 12 months; major device complication rates at 12 months
Secondary outcome measures: technical failures; secondary patency
Starting date February 2003. Trial completed recruitment in 2007 but still has not published results
Contact information Enrico Ascher, MD Maimonides Hospital, Brooklyn NY
Notes Sponsored by WL Gore & Associates
ClinicalTrials.gov identifier: NCT00205790
PTFE: polytetrafluoroethylene
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D A T A A N D A N A L Y S E S
Comparison 1. Above-knee autologous vein versus all other graft materials
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary patency at 3 months 4 466 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.20 [0.58, 2.48]
1.1 Autologous vein v PTFE 2 249 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.27 [0.41, 3.97]
1.2 Autologous vein v other
graft types
2 217 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.16 [0.45, 2.96]
2 Primary patency at 6 months 4 452 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.01 [0.56, 1.83]
2.1 Autologous vein v PTFE 2 245 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.12 [0.45, 2.78]
2.2 Autologous vein v other
graft types
2 207 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.94 [0.43, 2.05]
3 Primary patency at 12 months 4 440 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.73 [0.44, 1.22]
3.1 Autologous vein v PTFE 2 238 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.81 [0.37, 1.76]
3.2 Autologous vein v other
graft types
2 202 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.67 [0.34, 1.33]
4 Primary patency at 24 months 4 422 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.59 [0.37, 0.94]
4.1 Autologous vein vs PTFE 2 232 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.67 [0.34, 1.33]
4.2 Autologous vein vs other
graft types
2 190 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.52 [0.28, 0.99]
5 Primary patency at 60 months 3 269 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.47 [0.28, 0.80]
5.1 Autologous vein v PTFE 2 191 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.48 [0.25, 0.95]
5.2 Autologous vein vs other
graft type
1 78 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.44 [0.18, 1.07]
6 Secondary patency at 3 months 3 364 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.05 [0.47, 2.32]
6.1 Autologous vein v PTFE 1 147 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.08 [0.30, 3.87]
6.2 Autologous vein v other
graft types
2 217 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.03 [0.37, 2.83]
7 Secondary patency at 6 months 3 351 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.95 [0.49, 1.82]
7.1 Autologous vein v PTFE 1 143 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.98 [0.36, 2.69]
7.2 Autologous vein v other
graft types
2 208 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.92 [0.39, 2.19]
8 Secondary patency at 12 months 3 338 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.81 [0.45, 1.45]
8.1 Autologous vein v PTFE 1 136 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.99 [0.39, 2.51]
8.2 Autologous vein v other
graft types
2 202 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.71 [0.34, 1.50]
9 Secondary patency at 24 months 3 320 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.70 [0.41, 1.19]
9.1 Autologous vein v PTFE 1 130 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.83 [0.37, 1.87]
9.2 Autologous vein v other
graft type
2 190 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.62 [0.31, 1.24]
10 Secondary patency at 60
months
2 176 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.41 [0.22, 0.74]
10.1 Autologous vein v PTFE 1 98 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.44 [0.20, 0.99]
10.2 Autologous vein v other
graft types
1 78 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.37 [0.15, 0.90]
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Comparison 2. Above-knee PTFE versus all other graft materials
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary patency at 3 months 2 312 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.36 [0.81, 6.87]
1.1 PTFE v HUV 1 93 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.55 [0.26, 9.33]
1.2 PTFE v Dacron 1 219 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.97 [0.78, 11.25]
2 Primary patency at 6 months 5 824 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.11 [1.37, 3.25]
2.1 PTFE v HUV 1 90 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.56 [0.69, 9.47]
2.2 PTFE v Dacron 2 421 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.57 [0.79, 3.11]
2.3 PTFE v PTFE with vein
cuff
1 139 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.80 [0.57, 5.60]
2.4 PTFE v FUSION
BIOLINE
1 174 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.99 [1.43, 6.26]
3 Primary patency at 12 months 6 1088 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.23 [0.93, 1.64]
3.1 PTFE v HUV 1 83 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.17 [1.04, 9.64]
3.2 PTFE v Dacron 4 875 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.24 [0.91, 1.70]
3.3 PTFE v PTFE with vein
cuff
1 130 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.64 [0.26, 1.56]
4 Primary patency at 24 months 6 945 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.31 [1.00, 1.71]
4.1 PTFE V HUV 1 82 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.80 [1.76, 13.06]
4.2 PTFE V Dacron 4 764 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.23 [0.92, 1.65]
4.3 PTFE v PTFE with vein
cuff
1 99 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.86 [0.37, 2.02]
5 Primary patency at 60 months 3 316 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.06 [1.28, 3.31]
5.1 PTFE v HUV 1 69 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.75 [1.46, 9.62]
5.2 PTFE v Dacron 2 247 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.67 [0.96, 2.90]
6 Secondary patency at 3 months 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
6.1 PTFE v HUV 1 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Secondary patency at 6 months 2 318 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.32 [0.48, 3.62]
7.1 PTFE v HUV 1 93 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.76 [0.42, 7.44]
7.2 PTFE v Dacron 1 225 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.01 [0.25, 4.13]
8 Secondary patency at 12 months 4 806 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.18 [0.80, 1.74]
8.1 PTFE v HUV 1 93 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.60 [0.43, 5.89]
8.2 PTFE v Dacron 2 581 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.19 [0.76, 1.86]
8.3 PTFE v PTFE with vein
cuff
1 132 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.99 [0.39, 2.52]
9 Secondary patency at 24 months 4 700 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.66 [1.18, 2.33]
9.1 PTFE V HUV 1 93 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.01 [1.44, 11.17]
9.2 PTFE v Dacron 2 528 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.54 [1.04, 2.28]
9.3 PTFE v PTFE with vein
cuff
1 79 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.22 [0.48, 3.06]
10 Secondary patency at 60
months
2 260 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.86 [1.73, 4.72]
10.1 PTFE v HUV 1 93 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.87 [1.65, 9.05]
10.2 PTFE v Dacron 1 167 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.43 [1.31, 4.53]
11 Limb salvage at 1 month 2 560 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.68 [0.12, 3.98]
11.1 PTFE v Dacron 1 410 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.14 [0.01, 2.20]
11.2 PTFE v PTFE with vein
cuff
1 150 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.02 [0.21, 19.72]
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12 Limb salvage at 24 months 2 389 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.73 [0.33, 1.62]
12.1 PTFE v Dacron 1 322 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.82 [0.27, 2.48]
12.2 PTFE v PTFE with vein
cuff
1 67 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.64 [0.20, 2.04]
Comparison 3. Above-knee heparin bonded Dacron versus all other graft materials
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary patency at 12 months 2 294 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.58 [0.34, 0.98]
1.1 HBD v HUV 1 123 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.47 [0.20, 1.12]
1.2 HBD v PTFE 1 171 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.65 [0.34, 1.25]
2 Primary patency at 24 months 2 282 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.62 [0.38, 1.02]
2.1 HBD v HUV 1 117 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.59 [0.26, 1.33]
2.2 HBD v PTFE 1 165 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.64 [0.34, 1.19]
3 Primary patency at 60 months 2 232 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.55 [0.33, 0.93]
3.1 HBD v HUV 1 86 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.07 [0.45, 2.51]
3.2 HBD v PTFE 1 146 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.38 [0.20, 0.72]
Comparison 4. Above-knee externally supported graft versus unsupported graft materials
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary patency at 6 months 2 299 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.28 [0.71, 2.31]
1.1 Externally supported
dacron versus unsupported
dacron
1 253 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.29 [0.69, 2.39]
1.2 Externally supported
PTFE versus unsupported
PTFE
1 46 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.21 [0.16, 9.25]
2 Primary patency at 12 months 2 286 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.78 [1.06, 2.98]
2.1 Externally supported
dacron versus unsupported
dacron
1 246 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.71 [0.99, 2.93]
2.2 Externally supported
PTFE versus unsupported
PTFE
1 40 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.73 [0.49, 15.28]
3 Primary patency at 24 months 2 270 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.08 [1.29, 3.35]
3.1 Externally supported
dacron versus unsupported
dacron
1 240 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.09 [1.26, 3.46]
3.2 Externally supported
PTFE versus unsupported
PTFE
1 30 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.01 [0.46, 8.76]
4 Secondary patency at 6 months 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
58Graft type for femoro-popliteal bypass surgery (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
5 Secondary patency at 12 months 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
6 Secondary patency at 24 months 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
Comparison 5. Above-knee polyurethane (PUR) versus all other graft materials
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary patency at 3 months 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
2 Primary patency at 6 months 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
3 Primary patency at 12 months 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
4 Secondary patency at 3 months 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
5 Secondary patency at 6 months 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
6 Secondary patency at 12 months 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
Comparison 6. Below-knee PTFE versus all other graft materials
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary patency at 6 months 4 319 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.12 [0.67, 1.87]
1.1 PTFE v ringed PTFE 1 44 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.47 [0.32, 6.71]
1.2 PTFE v PTFE with vein
cuff
2 247 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.00 [0.56, 1.78]
1.3 PTFE v FUSION
BIOLINE
1 28 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.96 [0.39, 9.83]
2 Primary patency at 12 months 4 305 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.96 [0.60, 1.55]
2.1 PTFE v Dacron 1 45 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.47 [0.12, 1.79]
2.2 PTFE v PTFE with vein
cuff
2 224 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.02 [0.59, 1.76]
2.3 PTFE v ringed PTFE 1 36 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.48 [0.35, 6.24]
3 Primary patency at 24 months 4 250 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.94 [0.56, 1.57]
3.1 PTFE v Dacron 1 40 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.41 [0.12, 1.42]
3.2 PTFE v PTFE with vein
cuff
2 182 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.08 [0.58, 2.01]
3.3 PTFE v ringed PTFE 1 28 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.32 [0.31, 5.67]
4 Primary patency at 36 months 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
4.1 PTFE v PTFE with vein
cuff
1 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Secondary patency at 3 months 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
5.1 PTFE v HUV 1 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Secondary patency at 6 months 2 242 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.21 [0.69, 2.13]
6.1 PTFE v HUV 1 71 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.01 [1.12, 8.07]
6.2 PTFE v PTFE with vein
cuff
1 171 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.79 [0.40, 1.56]
7 Secondary patency at 12 months 3 325 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.48 [0.94, 2.34]
7.1 PTFE v HUV 1 101 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.46 [1.10, 5.49]
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7.2 PTFE v PTFE with vein
cuff
2 224 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.16 [0.66, 2.03]
8 Secondary patency at 24 months 3 269 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.72 [1.05, 2.80]
8.1 PTFE v HUV 1 88 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.40 [1.45, 7.97]
8.2 PTFE v PTFE with vein
cuff
2 181 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.22 [0.67, 2.23]
9 Secondary patency at 36 months 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
9.1 PTFE v PTFE with vein
cuff
1 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Limb salvage at 12 months 2 225 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.35 [0.72, 2.55]
10.1 PTFE v PTFE with vein
cuff
2 225 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.35 [0.72, 2.55]
11 Limb salvage at 24 months 2 196 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.34 [0.72, 2.49]
11.1 PTFE v PTFE with vein
cuff
2 196 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.34 [0.72, 2.49]
Comparison 7. Below-knee heparin bonded Dacron versus all other graft materials
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Primary patency at 3 months 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
1.1 HBD v PTFE 1 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Primary patency at 6 months 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
2.1 HBD v PTFE 1 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Primary patency at 12 months 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
3.1 HBD v PTFE 1 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Primary patency at 24 months 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
4.1 HBD v PTFE 1 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Primary patency at 60 months 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
5.1 HBD v PTFE 1 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Above-knee autologous vein versus all other graft materials, Outcome 1
Primary patency at 3 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 1 Above-knee autologous vein versus all other graft materials
Outcome: 1 Primary patency at 3 months
Study or subgroup Vein Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Autologous vein v PTFE
Ballotta 2003 0/51 0/51 Not estimable
Klinkert 2003 7/71 6/76 40.5 % 1.27 [ 0.41, 3.97 ]
Subtotal (95% CI) 122 127 40.5 % 1.27 [ 0.41, 3.97 ]
Total events: 7 (Vein), 6 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
2 Autologous vein v other graft types
Solakovic 2008 6/58 5/61 34.2 % 1.29 [ 0.37, 4.44 ]
Tofigh 2007 4/49 4/49 25.2 % 1.00 [ 0.24, 4.22 ]
Subtotal (95% CI) 107 110 59.5 % 1.16 [ 0.45, 2.96 ]
Total events: 10 (Vein), 9 (Other graft material)
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
Total (95% CI) 229 237 100.0 % 1.20 [ 0.58, 2.48 ]
Total events: 17 (Vein), 15 (Other graft material)
Heterogeneity: Chi2 = 0.09, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.90), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours vein Favours other graft type
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Analysis 1.2. Comparison 1 Above-knee autologous vein versus all other graft materials, Outcome 2
Primary patency at 6 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 1 Above-knee autologous vein versus all other graft materials
Outcome: 2 Primary patency at 6 months
Study or subgroup Vein Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Autologous vein v PTFE
Ballotta 2003 0/51 0/51 Not estimable
Klinkert 2003 11/68 11/75 42.6 % 1.12 [ 0.45, 2.78 ]
Subtotal (95% CI) 119 126 42.6 % 1.12 [ 0.45, 2.78 ]
Total events: 11 (Vein), 11 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
2 Autologous vein v other graft types
Solakovic 2008 8/56 9/59 33.3 % 0.93 [ 0.33, 2.58 ]
Tofigh 2007 6/47 6/45 24.0 % 0.95 [ 0.28, 3.18 ]
Subtotal (95% CI) 103 104 57.4 % 0.94 [ 0.43, 2.05 ]
Total events: 14 (Vein), 15 (Other graft material)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
Total (95% CI) 222 230 100.0 % 1.01 [ 0.56, 1.83 ]
Total events: 25 (Vein), 26 (Other graft material)
Heterogeneity: Chi2 = 0.09, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.77), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours vein Favours other graft type
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Analysis 1.3. Comparison 1 Above-knee autologous vein versus all other graft materials, Outcome 3
Primary patency at 12 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 1 Above-knee autologous vein versus all other graft materials
Outcome: 3 Primary patency at 12 months
Study or subgroup Vein Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Autologous vein v PTFE
Ballotta 2003 0/51 2/51 3.4 % 0.13 [ 0.01, 2.15 ]
Klinkert 2003 14/65 16/71 40.2 % 0.94 [ 0.42, 2.12 ]
Subtotal (95% CI) 116 122 43.6 % 0.81 [ 0.37, 1.76 ]
Total events: 14 (Vein), 18 (Other graft material)
Heterogeneity: Chi2 = 1.76, df = 1 (P = 0.18); I2 =43%
Test for overall effect: Z = 0.53 (P = 0.60)
2 Autologous vein v other graft types
Solakovic 2008 10/54 13/57 31.4 % 0.77 [ 0.31, 1.93 ]
Tofigh 2007 7/46 11/45 25.0 % 0.56 [ 0.20, 1.57 ]
Subtotal (95% CI) 100 102 56.4 % 0.67 [ 0.34, 1.33 ]
Total events: 17 (Vein), 24 (Other graft material)
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
Total (95% CI) 216 224 100.0 % 0.73 [ 0.44, 1.22 ]
Total events: 31 (Vein), 42 (Other graft material)
Heterogeneity: Chi2 = 2.09, df = 3 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Chi2 = 0.13, df = 1 (P = 0.72), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours vein Favours other graft type
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Analysis 1.4. Comparison 1 Above-knee autologous vein versus all other graft materials, Outcome 4
Primary patency at 24 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 1 Above-knee autologous vein versus all other graft materials
Outcome: 4 Primary patency at 24 months
Study or subgroup Vein Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Autologous vein vs PTFE
Ballotta 2003 1/51 5/51 8.0 % 0.25 [ 0.05, 1.27 ]
Klinkert 2003 17/61 22/69 38.5 % 0.83 [ 0.39, 1.75 ]
Subtotal (95% CI) 112 120 46.6 % 0.67 [ 0.34, 1.33 ]
Total events: 18 (Vein), 27 (Other graft material)
Heterogeneity: Chi2 = 1.74, df = 1 (P = 0.19); I2 =42%
Test for overall effect: Z = 1.15 (P = 0.25)
2 Autologous vein vs other graft types
Solakovic 2008 12/50 19/55 30.9 % 0.61 [ 0.26, 1.40 ]
Tofigh 2007 7/42 14/43 22.5 % 0.43 [ 0.16, 1.15 ]
Subtotal (95% CI) 92 98 53.4 % 0.52 [ 0.28, 0.99 ]
Total events: 19 (Vein), 33 (Other graft material)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.99 (P = 0.046)
Total (95% CI) 204 218 100.0 % 0.59 [ 0.37, 0.94 ]
Total events: 37 (Vein), 60 (Other graft material)
Heterogeneity: Chi2 = 2.28, df = 3 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 2.24 (P = 0.025)
Test for subgroup differences: Chi2 = 0.27, df = 1 (P = 0.60), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours vein Favours other graft type
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Analysis 1.5. Comparison 1 Above-knee autologous vein versus all other graft materials, Outcome 5
Primary patency at 60 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 1 Above-knee autologous vein versus all other graft materials
Outcome: 5 Primary patency at 60 months
Study or subgroup Vein Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Autologous vein v PTFE
Ballotta 2003 3/46 8/46 18.1 % 0.36 [ 0.10, 1.26 ]
Klinkert 2003 18/43 32/56 45.5 % 0.55 [ 0.25, 1.20 ]
Subtotal (95% CI) 89 102 63.6 % 0.48 [ 0.25, 0.95 ]
Total events: 21 (Vein), 40 (Other graft material)
Heterogeneity: Chi2 = 0.30, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 2.12 (P = 0.034)
2 Autologous vein vs other graft type
Solakovic 2008 14/36 25/42 36.4 % 0.44 [ 0.18, 1.07 ]
Subtotal (95% CI) 36 42 36.4 % 0.44 [ 0.18, 1.07 ]
Total events: 14 (Vein), 25 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.071)
Total (95% CI) 125 144 100.0 % 0.47 [ 0.28, 0.80 ]
Total events: 35 (Vein), 65 (Other graft material)
Heterogeneity: Chi2 = 0.33, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.78 (P = 0.0054)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
0.002 0.1 1 10 500
Favours vein Favours other graft type
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Analysis 1.6. Comparison 1 Above-knee autologous vein versus all other graft materials, Outcome 6
Secondary patency at 3 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 1 Above-knee autologous vein versus all other graft materials
Outcome: 6 Secondary patency at 3 months
Study or subgroup Vein Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Autologous vein v PTFE
Klinkert 2003 5/71 5/76 38.5 % 1.08 [ 0.30, 3.87 ]
Subtotal (95% CI) 71 76 38.5 % 1.08 [ 0.30, 3.87 ]
Total events: 5 (Vein), 5 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
2 Autologous vein v other graft types
Solakovic 2008 4/58 4/61 30.9 % 1.06 [ 0.25, 4.41 ]
Tofigh 2007 4/49 4/49 30.5 % 1.00 [ 0.24, 4.22 ]
Subtotal (95% CI) 107 110 61.5 % 1.03 [ 0.37, 2.83 ]
Total events: 8 (Vein), 8 (Other graft material)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Total (95% CI) 178 186 100.0 % 1.05 [ 0.47, 2.32 ]
Total events: 13 (Vein), 13 (Other graft material)
Heterogeneity: Chi2 = 0.01, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.96), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours vein Favours other graft type
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Analysis 1.7. Comparison 1 Above-knee autologous vein versus all other graft materials, Outcome 7
Secondary patency at 6 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 1 Above-knee autologous vein versus all other graft materials
Outcome: 7 Secondary patency at 6 months
Study or subgroup Vein Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Autologous vein v PTFE
Klinkert 2003 8/68 9/75 42.2 % 0.98 [ 0.36, 2.69 ]
Subtotal (95% CI) 68 75 42.2 % 0.98 [ 0.36, 2.69 ]
Total events: 8 (Vein), 9 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
2 Autologous vein v other graft types
Solakovic 2008 5/56 7/60 30.4 % 0.75 [ 0.23, 2.45 ]
Tofigh 2007 6/47 5/45 27.4 % 1.17 [ 0.33, 4.09 ]
Subtotal (95% CI) 103 105 57.8 % 0.92 [ 0.39, 2.19 ]
Total events: 11 (Vein), 12 (Other graft material)
Heterogeneity: Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
Total (95% CI) 171 180 100.0 % 0.95 [ 0.49, 1.82 ]
Total events: 19 (Vein), 21 (Other graft material)
Heterogeneity: Chi2 = 0.27, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours vein Favours other graft type
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Analysis 1.8. Comparison 1 Above-knee autologous vein versus all other graft materials, Outcome 8
Secondary patency at 12 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 1 Above-knee autologous vein versus all other graft materials
Outcome: 8 Secondary patency at 12 months
Study or subgroup Vein Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Autologous vein v PTFE
Klinkert 2003 10/65 11/71 39.1 % 0.99 [ 0.39, 2.51 ]
Subtotal (95% CI) 65 71 39.1 % 0.99 [ 0.39, 2.51 ]
Total events: 10 (Vein), 11 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.99)
2 Autologous vein v other graft types
Solakovic 2008 7/54 10/57 31.8 % 0.70 [ 0.25, 1.97 ]
Tofigh 2007 7/46 9/45 29.2 % 0.72 [ 0.25, 2.11 ]
Subtotal (95% CI) 100 102 60.9 % 0.71 [ 0.34, 1.50 ]
Total events: 14 (Vein), 19 (Other graft material)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
Total (95% CI) 165 173 100.0 % 0.81 [ 0.45, 1.45 ]
Total events: 24 (Vein), 30 (Other graft material)
Heterogeneity: Chi2 = 0.30, df = 2 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Chi2 = 0.30, df = 1 (P = 0.59), I2 =0.0%
0.002 0.1 1 10 500
Favours vein Favours other graft type
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Analysis 1.9. Comparison 1 Above-knee autologous vein versus all other graft materials, Outcome 9
Secondary patency at 24 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 1 Above-knee autologous vein versus all other graft materials
Outcome: 9 Secondary patency at 24 months
Study or subgroup Vein Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Autologous vein v PTFE
Klinkert 2003 13/61 17/69 41.7 % 0.83 [ 0.37, 1.87 ]
Subtotal (95% CI) 61 69 41.7 % 0.83 [ 0.37, 1.87 ]
Total events: 13 (Vein), 17 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
2 Autologous vein v other graft type
Solakovic 2008 9/50 14/55 32.5 % 0.65 [ 0.26, 1.63 ]
Tofigh 2007 7/42 11/43 25.8 % 0.59 [ 0.21, 1.66 ]
Subtotal (95% CI) 92 98 58.3 % 0.62 [ 0.31, 1.24 ]
Total events: 16 (Vein), 25 (Other graft material)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
Total (95% CI) 153 167 100.0 % 0.70 [ 0.41, 1.19 ]
Total events: 29 (Vein), 42 (Other graft material)
Heterogeneity: Chi2 = 0.30, df = 2 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Chi2 = 0.28, df = 1 (P = 0.60), I2 =0.0%
0.002 0.1 1 10 500
Favours vein Favours other graft type
69Graft type for femoro-popliteal bypass surgery (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.10. Comparison 1 Above-knee autologous vein versus all other graft materials, Outcome 10
Secondary patency at 60 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 1 Above-knee autologous vein versus all other graft materials
Outcome: 10 Secondary patency at 60 months
Study or subgroup Vein Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Autologous vein v PTFE
Klinkert 2003 14/43 29/55 55.8 % 0.44 [ 0.20, 0.99 ]
Subtotal (95% CI) 43 55 55.8 % 0.44 [ 0.20, 0.99 ]
Total events: 14 (Vein), 29 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 1.99 (P = 0.047)
2 Autologous vein v other graft types
Solakovic 2008 10/36 22/42 44.2 % 0.37 [ 0.15, 0.90 ]
Subtotal (95% CI) 36 42 44.2 % 0.37 [ 0.15, 0.90 ]
Total events: 10 (Vein), 22 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.029)
Total (95% CI) 79 97 100.0 % 0.41 [ 0.22, 0.74 ]
Total events: 24 (Vein), 51 (Other graft material)
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 2.94 (P = 0.0033)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours vein Favours other graft type
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Analysis 2.1. Comparison 2 Above-knee PTFE versus all other graft materials, Outcome 1 Primary patency
at 3 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 2 Above-knee PTFE versus all other graft materials
Outcome: 1 Primary patency at 3 months
Study or subgroup PTFE Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 PTFE v HUV
Aalders 1992 3/46 2/47 35.6 % 1.55 [ 0.26, 9.33 ]
Subtotal (95% CI) 46 47 35.6 % 1.55 [ 0.26, 9.33 ]
Total events: 3 (PTFE), 2 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
2 PTFE v Dacron
Abbot 1997 7/113 2/106 64.4 % 2.97 [ 0.78, 11.25 ]
Subtotal (95% CI) 113 106 64.4 % 2.97 [ 0.78, 11.25 ]
Total events: 7 (PTFE), 2 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
Total (95% CI) 159 153 100.0 % 2.36 [ 0.81, 6.87 ]
Total events: 10 (PTFE), 4 (Other graft material)
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Chi2 = 0.32, df = 1 (P = 0.57), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours PTFE Favours other graft type
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Analysis 2.2. Comparison 2 Above-knee PTFE versus all other graft materials, Outcome 2 Primary patency
at 6 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 2 Above-knee PTFE versus all other graft materials
Outcome: 2 Primary patency at 6 months
Study or subgroup PTFE Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 PTFE v HUV
Aalders 1992 7/44 3/46 11.0 % 2.56 [ 0.69, 9.47 ]
Subtotal (95% CI) 44 46 11.0 % 2.56 [ 0.69, 9.47 ]
Total events: 7 (PTFE), 3 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
2 PTFE v Dacron
Abbot 1997 14/101 9/95 25.0 % 1.52 [ 0.64, 3.63 ]
van Det 2009 8/112 5/113 15.1 % 1.64 [ 0.54, 5.03 ]
Subtotal (95% CI) 213 208 40.0 % 1.57 [ 0.79, 3.11 ]
Total events: 22 (PTFE), 14 (Other graft material)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
3 PTFE v PTFE with vein cuff
Stonebridge 1997 8/67 5/72 14.5 % 1.80 [ 0.57, 5.60 ]
Subtotal (95% CI) 67 72 14.5 % 1.80 [ 0.57, 5.60 ]
Total events: 8 (PTFE), 5 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
4 PTFE v FUSION BIOLINE
Lumsden 2015 25/86 10/88 34.4 % 2.99 [ 1.43, 6.26 ]
Subtotal (95% CI) 86 88 34.4 % 2.99 [ 1.43, 6.26 ]
Total events: 25 (PTFE), 10 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 2.90 (P = 0.0037)
Total (95% CI) 410 414 100.0 % 2.11 [ 1.37, 3.25 ]
Total events: 62 (PTFE), 32 (Other graft material)
Heterogeneity: Chi2 = 1.75, df = 4 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 3.37 (P = 0.00075)
Test for subgroup differences: Chi2 = 1.74, df = 3 (P = 0.63), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours PTFE Favours other graft type
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Analysis 2.3. Comparison 2 Above-knee PTFE versus all other graft materials, Outcome 3 Primary patency
at 12 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 2 Above-knee PTFE versus all other graft materials
Outcome: 3 Primary patency at 12 months
Study or subgroup PTFE Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 PTFE v HUV
Aalders 1992 11/41 4/42 6.6 % 3.17 [ 1.04, 9.64 ]
Subtotal (95% CI) 41 42 6.6 % 3.17 [ 1.04, 9.64 ]
Total events: 11 (PTFE), 4 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 2.04 (P = 0.042)
2 PTFE v Dacron
Abbot 1997 21/87 21/86 17.0 % 0.98 [ 0.49, 1.97 ]
Jensen 2007 58/181 47/184 39.8 % 1.37 [ 0.87, 2.16 ]
Post 2001 14/55 12/66 10.8 % 1.53 [ 0.64, 3.65 ]
van Det 2009 18/108 17/108 15.6 % 1.07 [ 0.52, 2.20 ]
Subtotal (95% CI) 431 444 83.3 % 1.24 [ 0.91, 1.70 ]
Total events: 111 (PTFE), 97 (Other graft material)
Heterogeneity: Chi2 = 1.01, df = 3 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.36 (P = 0.18)
3 PTFE v PTFE with vein cuff
Stonebridge 1997 9/63 14/67 10.1 % 0.64 [ 0.26, 1.56 ]
Subtotal (95% CI) 63 67 10.1 % 0.64 [ 0.26, 1.56 ]
Total events: 9 (PTFE), 14 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
Total (95% CI) 535 553 100.0 % 1.23 [ 0.93, 1.64 ]
Total events: 131 (PTFE), 115 (Other graft material)
Heterogeneity: Chi2 = 5.86, df = 5 (P = 0.32); I2 =15%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Chi2 = 4.85, df = 2 (P = 0.09), I2 =59%
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Analysis 2.4. Comparison 2 Above-knee PTFE versus all other graft materials, Outcome 4 Primary patency
at 24 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 2 Above-knee PTFE versus all other graft materials
Outcome: 4 Primary patency at 24 months
Study or subgroup PTFE Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 PTFE V HUV
Aalders 1992 16/41 4/41 7.0 % 4.80 [ 1.76, 13.06 ]
Subtotal (95% CI) 41 41 7.0 % 4.80 [ 1.76, 13.06 ]
Total events: 16 (PTFE), 4 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 3.07 (P = 0.0022)
2 PTFE V Dacron
Abbot 1997 29/68 30/66 15.3 % 0.89 [ 0.45, 1.76 ]
Jensen 2007 92/164 80/158 37.0 % 1.24 [ 0.80, 1.93 ]
Post 2001 16/43 15/59 9.8 % 1.74 [ 0.74, 4.06 ]
van Det 2009 36/100 32/106 21.1 % 1.30 [ 0.73, 2.32 ]
Subtotal (95% CI) 375 389 83.2 % 1.23 [ 0.92, 1.65 ]
Total events: 173 (PTFE), 157 (Other graft material)
Heterogeneity: Chi2 = 1.52, df = 3 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
3 PTFE v PTFE with vein cuff
Stonebridge 1997 13/44 18/55 9.8 % 0.86 [ 0.37, 2.02 ]
Subtotal (95% CI) 44 55 9.8 % 0.86 [ 0.37, 2.02 ]
Total events: 13 (PTFE), 18 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.74)
Total (95% CI) 460 485 100.0 % 1.31 [ 1.00, 1.71 ]
Total events: 202 (PTFE), 179 (Other graft material)
Heterogeneity: Chi2 = 9.06, df = 5 (P = 0.11); I2 =45%
Test for overall effect: Z = 1.98 (P = 0.048)
Test for subgroup differences: Chi2 = 7.54, df = 2 (P = 0.02), I2 =73%
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Analysis 2.5. Comparison 2 Above-knee PTFE versus all other graft materials, Outcome 5 Primary patency
at 60 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 2 Above-knee PTFE versus all other graft materials
Outcome: 5 Primary patency at 60 months
Study or subgroup PTFE Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 PTFE v HUV
Aalders 1992 25/38 10/31 25.6 % 3.75 [ 1.46, 9.62 ]
Subtotal (95% CI) 38 31 25.6 % 3.75 [ 1.46, 9.62 ]
Total events: 25 (PTFE), 10 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 2.75 (P = 0.0059)
2 PTFE v Dacron
Abbot 1997 35/40 35/40 13.1 % 1.00 [ 0.27, 3.73 ]
van Det 2009 51/80 42/87 61.3 % 1.87 [ 1.01, 3.43 ]
Subtotal (95% CI) 120 127 74.4 % 1.67 [ 0.96, 2.90 ]
Total events: 86 (PTFE), 77 (Other graft material)
Heterogeneity: Chi2 = 0.71, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.82 (P = 0.069)
Total (95% CI) 158 158 100.0 % 2.06 [ 1.28, 3.31 ]
Total events: 111 (PTFE), 87 (Other graft material)
Heterogeneity: Chi2 = 2.81, df = 2 (P = 0.24); I2 =29%
Test for overall effect: Z = 2.96 (P = 0.0031)
Test for subgroup differences: Chi2 = 2.11, df = 1 (P = 0.15), I2 =53%
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Analysis 2.6. Comparison 2 Above-knee PTFE versus all other graft materials, Outcome 6 Secondary
patency at 3 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 2 Above-knee PTFE versus all other graft materials
Outcome: 6 Secondary patency at 3 months
Study or subgroup PTFE Other graft material
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 PTFE v HUV
Aalders 1992 3/46 2/47 1.55 [ 0.26, 9.33 ]
0.002 0.1 1 10 500
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Analysis 2.7. Comparison 2 Above-knee PTFE versus all other graft materials, Outcome 7 Secondary
patency at 6 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 2 Above-knee PTFE versus all other graft materials
Outcome: 7 Secondary patency at 6 months
Study or subgroup PTFE Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 PTFE v HUV
Aalders 1992 5/46 3/47 48.8 % 1.76 [ 0.42, 7.44 ]
Subtotal (95% CI) 46 47 48.8 % 1.76 [ 0.42, 7.44 ]
Total events: 5 (PTFE), 3 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
2 PTFE v Dacron
van Det 2009 4/112 4/113 51.2 % 1.01 [ 0.25, 4.13 ]
Subtotal (95% CI) 112 113 51.2 % 1.01 [ 0.25, 4.13 ]
Total events: 4 (PTFE), 4 (Other graft material)
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(. . . Continued)
Study or subgroup PTFE Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Total (95% CI) 158 160 100.0 % 1.32 [ 0.48, 3.62 ]
Total events: 9 (PTFE), 7 (Other graft material)
Heterogeneity: Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.59)
Test for subgroup differences: Chi2 = 0.29, df = 1 (P = 0.59), I2 =0.0%
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Analysis 2.8. Comparison 2 Above-knee PTFE versus all other graft materials, Outcome 8 Secondary
patency at 12 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 2 Above-knee PTFE versus all other graft materials
Outcome: 8 Secondary patency at 12 months
Study or subgroup PTFE Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 PTFE v HUV
Aalders 1992 6/46 4/47 8.7 % 1.60 [ 0.43, 5.89 ]
Subtotal (95% CI) 46 47 8.7 % 1.60 [ 0.43, 5.89 ]
Total events: 6 (PTFE), 4 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
2 PTFE v Dacron
Jensen 2007 40/181 31/184 55.6 % 1.40 [ 0.83, 2.34 ]
van Det 2009 9/108 12/108 18.5 % 0.73 [ 0.30, 1.79 ]
Subtotal (95% CI) 289 292 74.0 % 1.19 [ 0.76, 1.86 ]
Total events: 49 (PTFE), 43 (Other graft material)
Heterogeneity: Chi2 = 1.51, df = 1 (P = 0.22); I2 =34%
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(. . . Continued)
Study or subgroup PTFE Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Test for overall effect: Z = 0.75 (P = 0.45)
3 PTFE v PTFE with vein cuff
Stonebridge 1997 10/63 11/69 17.2 % 0.99 [ 0.39, 2.52 ]
Subtotal (95% CI) 63 69 17.2 % 0.99 [ 0.39, 2.52 ]
Total events: 10 (PTFE), 11 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Total (95% CI) 398 408 100.0 % 1.18 [ 0.80, 1.74 ]
Total events: 65 (PTFE), 58 (Other graft material)
Heterogeneity: Chi2 = 1.84, df = 3 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Chi2 = 0.34, df = 2 (P = 0.85), I2 =0.0%
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Analysis 2.9. Comparison 2 Above-knee PTFE versus all other graft materials, Outcome 9 Secondary
patency at 24 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 2 Above-knee PTFE versus all other graft materials
Outcome: 9 Secondary patency at 24 months
Study or subgroup PTFE Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 PTFE V HUV
Aalders 1992 14/46 4/47 11.1 % 4.01 [ 1.44, 11.17 ]
Subtotal (95% CI) 46 47 11.1 % 4.01 [ 1.44, 11.17 ]
Total events: 14 (PTFE), 4 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 2.66 (P = 0.0078)
2 PTFE v Dacron
Jensen 2007 57/164 38/158 51.0 % 1.67 [ 1.04, 2.70 ]
van Det 2009 21/100 18/106 24.1 % 1.30 [ 0.65, 2.60 ]
Subtotal (95% CI) 264 264 75.1 % 1.54 [ 1.04, 2.28 ]
Total events: 78 (PTFE), 56 (Other graft material)
Heterogeneity: Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.15 (P = 0.032)
3 PTFE v PTFE with vein cuff
Stonebridge 1997 13/33 16/46 13.7 % 1.22 [ 0.48, 3.06 ]
Subtotal (95% CI) 33 46 13.7 % 1.22 [ 0.48, 3.06 ]
Total events: 13 (PTFE), 16 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
Total (95% CI) 343 357 100.0 % 1.66 [ 1.18, 2.33 ]
Total events: 105 (PTFE), 76 (Other graft material)
Heterogeneity: Chi2 = 3.78, df = 3 (P = 0.29); I2 =21%
Test for overall effect: Z = 2.90 (P = 0.0037)
Test for subgroup differences: Chi2 = 3.43, df = 2 (P = 0.18), I2 =42%
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Analysis 2.10. Comparison 2 Above-knee PTFE versus all other graft materials, Outcome 10 Secondary
patency at 60 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 2 Above-knee PTFE versus all other graft materials
Outcome: 10 Secondary patency at 60 months
Study or subgroup PTFE Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 PTFE v HUV
Aalders 1992 23/46 9/47 34.7 % 3.87 [ 1.65, 9.05 ]
Subtotal (95% CI) 46 47 34.7 % 3.87 [ 1.65, 9.05 ]
Total events: 23 (PTFE), 9 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 3.11 (P = 0.0018)
2 PTFE v Dacron
van Det 2009 40/80 25/87 65.3 % 2.43 [ 1.31, 4.53 ]
Subtotal (95% CI) 80 87 65.3 % 2.43 [ 1.31, 4.53 ]
Total events: 40 (PTFE), 25 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 2.81 (P = 0.0050)
Total (95% CI) 126 134 100.0 % 2.86 [ 1.73, 4.72 ]
Total events: 63 (PTFE), 34 (Other graft material)
Heterogeneity: Chi2 = 0.74, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 4.10 (P = 0.000041)
Test for subgroup differences: Chi2 = 0.74, df = 1 (P = 0.39), I2 =0.0%
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Analysis 2.11. Comparison 2 Above-knee PTFE versus all other graft materials, Outcome 11 Limb salvage
at 1 month.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 2 Above-knee PTFE versus all other graft materials
Outcome: 11 Limb salvage at 1 month
Study or subgroup PTFE Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 PTFE v Dacron
Jensen 2007 0/203 2/207 40.3 % 0.14 [ 0.01, 2.20 ]
Subtotal (95% CI) 203 207 40.3 % 0.14 [ 0.01, 2.20 ]
Total events: 0 (PTFE), 2 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
2 PTFE v PTFE with vein cuff
Stonebridge 1997 2/74 1/76 59.7 % 2.02 [ 0.21, 19.72 ]
Subtotal (95% CI) 74 76 59.7 % 2.02 [ 0.21, 19.72 ]
Total events: 2 (PTFE), 1 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Total (95% CI) 277 283 100.0 % 0.68 [ 0.12, 3.98 ]
Total events: 2 (PTFE), 3 (Other graft material)
Heterogeneity: Chi2 = 2.15, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Chi2 = 2.15, df = 1 (P = 0.14), I2 =54%
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Analysis 2.12. Comparison 2 Above-knee PTFE versus all other graft materials, Outcome 12 Limb salvage
at 24 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 2 Above-knee PTFE versus all other graft materials
Outcome: 12 Limb salvage at 24 months
Study or subgroup PTFE Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 PTFE v Dacron
Jensen 2007 6/164 7/158 52.1 % 0.82 [ 0.27, 2.48 ]
Subtotal (95% CI) 164 158 52.1 % 0.82 [ 0.27, 2.48 ]
Total events: 6 (PTFE), 7 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
2 PTFE v PTFE with vein cuff
Stonebridge 1997 5/28 10/39 47.9 % 0.64 [ 0.20, 2.04 ]
Subtotal (95% CI) 28 39 47.9 % 0.64 [ 0.20, 2.04 ]
Total events: 5 (PTFE), 10 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
Total (95% CI) 192 197 100.0 % 0.73 [ 0.33, 1.62 ]
Total events: 11 (PTFE), 17 (Other graft material)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.77), I2 =0.0%
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Analysis 3.1. Comparison 3 Above-knee heparin bonded Dacron versus all other graft materials, Outcome
1 Primary patency at 12 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 3 Above-knee heparin bonded Dacron versus all other graft materials
Outcome: 1 Primary patency at 12 months
Study or subgroup HBD Other graft
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 HBD v HUV
Scharn 2008 8/56 18/67 36.6 % 0.47 [ 0.20, 1.12 ]
Subtotal (95% CI) 56 67 36.6 % 0.47 [ 0.20, 1.12 ]
Total events: 8 (HBD), 18 (Other graft)
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.090)
2 HBD v PTFE
Devine 2004 21/85 29/86 63.4 % 0.65 [ 0.34, 1.25 ]
Subtotal (95% CI) 85 86 63.4 % 0.65 [ 0.34, 1.25 ]
Total events: 21 (HBD), 29 (Other graft)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Total (95% CI) 141 153 100.0 % 0.58 [ 0.34, 0.98 ]
Total events: 29 (HBD), 47 (Other graft)
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 2.05 (P = 0.040)
Test for subgroup differences: Chi2 = 0.32, df = 1 (P = 0.57), I2 =0.0%
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Analysis 3.2. Comparison 3 Above-knee heparin bonded Dacron versus all other graft materials, Outcome
2 Primary patency at 24 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 3 Above-knee heparin bonded Dacron versus all other graft materials
Outcome: 2 Primary patency at 24 months
Study or subgroup HBD Other graft
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 HBD v HUV
Scharn 2008 11/53 20/64 36.3 % 0.59 [ 0.26, 1.33 ]
Subtotal (95% CI) 53 64 36.3 % 0.59 [ 0.26, 1.33 ]
Total events: 11 (HBD), 20 (Other graft)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
2 HBD v PTFE
Devine 2004 28/80 39/85 63.7 % 0.64 [ 0.34, 1.19 ]
Subtotal (95% CI) 80 85 63.7 % 0.64 [ 0.34, 1.19 ]
Total events: 28 (HBD), 39 (Other graft)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
Total (95% CI) 133 149 100.0 % 0.62 [ 0.38, 1.02 ]
Total events: 39 (HBD), 59 (Other graft)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.057)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
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Analysis 3.3. Comparison 3 Above-knee heparin bonded Dacron versus all other graft materials, Outcome
3 Primary patency at 60 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 3 Above-knee heparin bonded Dacron versus all other graft materials
Outcome: 3 Primary patency at 60 months
Study or subgroup HBD Other graft
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 HBD v HUV
Scharn 2008 21/37 27/49 36.7 % 1.07 [ 0.45, 2.51 ]
Subtotal (95% CI) 37 49 36.7 % 1.07 [ 0.45, 2.51 ]
Total events: 21 (HBD), 27 (Other graft)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
2 HBD v PTFE
Devine 2004 30/70 51/76 63.3 % 0.38 [ 0.20, 0.72 ]
Subtotal (95% CI) 70 76 63.3 % 0.38 [ 0.20, 0.72 ]
Total events: 30 (HBD), 51 (Other graft)
Heterogeneity: not applicable
Test for overall effect: Z = 2.94 (P = 0.0033)
Total (95% CI) 107 125 100.0 % 0.55 [ 0.33, 0.93 ]
Total events: 51 (HBD), 78 (Other graft)
Heterogeneity: Chi2 = 3.61, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 2.24 (P = 0.025)
Test for subgroup differences: Chi2 = 3.61, df = 1 (P = 0.06), I2 =72%
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Analysis 4.1. Comparison 4 Above-knee externally supported graft versus unsupported graft materials,
Outcome 1 Primary patency at 6 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 4 Above-knee externally supported graft versus unsupported graft materials
Outcome: 1 Primary patency at 6 months
Study or subgroup ExS graft Unsupported graft
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Externally supported dacron versus unsupported dacron
Vriens 2013 29/134 21/119 91.5 % 1.29 [ 0.69, 2.39 ]
Subtotal (95% CI) 134 119 91.5 % 1.29 [ 0.69, 2.39 ]
Total events: 29 (ExS graft), 21 (Unsupported graft)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
2 Externally supported PTFE versus unsupported PTFE
Gupta 1991 2/21 2/25 8.5 % 1.21 [ 0.16, 9.25 ]
Subtotal (95% CI) 21 25 8.5 % 1.21 [ 0.16, 9.25 ]
Total events: 2 (ExS graft), 2 (Unsupported graft)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
Total (95% CI) 155 144 100.0 % 1.28 [ 0.71, 2.31 ]
Total events: 31 (ExS graft), 23 (Unsupported graft)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
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Analysis 4.2. Comparison 4 Above-knee externally supported graft versus unsupported graft materials,
Outcome 2 Primary patency at 12 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 4 Above-knee externally supported graft versus unsupported graft materials
Outcome: 2 Primary patency at 12 months
Study or subgroup ExS graft Unsupported graft
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Externally supported dacron versus unsupported dacron
Vriens 2013 46/128 29/118 91.0 % 1.71 [ 0.99, 2.93 ]
Subtotal (95% CI) 128 118 91.0 % 1.71 [ 0.99, 2.93 ]
Total events: 46 (ExS graft), 29 (Unsupported graft)
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.054)
2 Externally supported PTFE versus unsupported PTFE
Gupta 1991 4/18 2/22 9.0 % 2.73 [ 0.49, 15.28 ]
Subtotal (95% CI) 18 22 9.0 % 2.73 [ 0.49, 15.28 ]
Total events: 4 (ExS graft), 2 (Unsupported graft)
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
Total (95% CI) 146 140 100.0 % 1.78 [ 1.06, 2.98 ]
Total events: 50 (ExS graft), 31 (Unsupported graft)
Heterogeneity: Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 2.18 (P = 0.029)
Test for subgroup differences: Chi2 = 0.26, df = 1 (P = 0.61), I2 =0.0%
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Analysis 4.3. Comparison 4 Above-knee externally supported graft versus unsupported graft materials,
Outcome 3 Primary patency at 24 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 4 Above-knee externally supported graft versus unsupported graft materials
Outcome: 3 Primary patency at 24 months
Study or subgroup ExS Dacron
Unsupported
Dacron
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Externally supported dacron versus unsupported dacron
Vriens 2013 71/124 45/116 89.5 % 2.09 [ 1.26, 3.46 ]
Subtotal (95% CI) 124 116 89.5 % 2.09 [ 1.26, 3.46 ]
Total events: 71 (ExS Dacron), 45 (Unsupported Dacron)
Heterogeneity: not applicable
Test for overall effect: Z = 2.85 (P = 0.0043)
2 Externally supported PTFE versus unsupported PTFE
Gupta 1991 6/13 5/17 10.5 % 2.01 [ 0.46, 8.76 ]
Subtotal (95% CI) 13 17 10.5 % 2.01 [ 0.46, 8.76 ]
Total events: 6 (ExS Dacron), 5 (Unsupported Dacron)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Total (95% CI) 137 133 100.0 % 2.08 [ 1.29, 3.35 ]
Total events: 77 (ExS Dacron), 50 (Unsupported Dacron)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 3.00 (P = 0.0027)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.96), I2 =0.0%
0.002 0.1 1 10 500
Favours ExS Favours Unsupported
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Analysis 4.4. Comparison 4 Above-knee externally supported graft versus unsupported graft materials,
Outcome 4 Secondary patency at 6 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 4 Above-knee externally supported graft versus unsupported graft materials
Outcome: 4 Secondary patency at 6 months
Study or subgroup ExS Dacron
Unsupported
Dacron
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Vriens 2013 11/134 9/119 1.09 [ 0.44, 2.72 ]
0.002 0.1 1 10 500
Favours ExS Favours Unsupported
Analysis 4.5. Comparison 4 Above-knee externally supported graft versus unsupported graft materials,
Outcome 5 Secondary patency at 12 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 4 Above-knee externally supported graft versus unsupported graft materials
Outcome: 5 Secondary patency at 12 months
Study or subgroup ExS Dacron
Unsupported
Dacron
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Vriens 2013 21/128 14/118 1.45 [ 0.71, 2.96 ]
0.002 0.1 1 10 500
Favours ExS Favours Unsupported
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Analysis 4.6. Comparison 4 Above-knee externally supported graft versus unsupported graft materials,
Outcome 6 Secondary patency at 24 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 4 Above-knee externally supported graft versus unsupported graft materials
Outcome: 6 Secondary patency at 24 months
Study or subgroup ExS Dacron
Unsupported
Dacron
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Vriens 2013 38/121 19/115 2.25 [ 1.24, 4.07 ]
0.002 0.1 1 10 500
Favours ExS Favours Unsupported
Analysis 5.1. Comparison 5 Above-knee polyurethane (PUR) versus all other graft materials, Outcome 1
Primary patency at 3 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 5 Above-knee polyurethane (PUR) versus all other graft materials
Outcome: 1 Primary patency at 3 months
Study or subgroup Polyurethane Dacron
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Gloor 1996 9/10 2/10 14.69 [ 2.64, 81.79 ]
0.002 0.1 1 10 500
Favours polyurethane Favours dacron
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Analysis 5.2. Comparison 5 Above-knee polyurethane (PUR) versus all other graft materials, Outcome 2
Primary patency at 6 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 5 Above-knee polyurethane (PUR) versus all other graft materials
Outcome: 2 Primary patency at 6 months
Study or subgroup Polyurethane Dacron
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Gloor 1996 9/10 4/10 8.07 [ 1.35, 48.38 ]
0.001 0.01 0.1 1 10 100 1000
Favours polyurethane Favours dacron
Analysis 5.3. Comparison 5 Above-knee polyurethane (PUR) versus all other graft materials, Outcome 3
Primary patency at 12 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 5 Above-knee polyurethane (PUR) versus all other graft materials
Outcome: 3 Primary patency at 12 months
Study or subgroup Polyurethane Dacron
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Gloor 1996 10/10 5/10 12.60 [ 1.75, 90.59 ]
0.002 0.1 1 10 500
Favours polyurethane Favours dacron
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Analysis 5.4. Comparison 5 Above-knee polyurethane (PUR) versus all other graft materials, Outcome 4
Secondary patency at 3 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 5 Above-knee polyurethane (PUR) versus all other graft materials
Outcome: 4 Secondary patency at 3 months
Study or subgroup Polyurethane Dacron
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Gloor 1996 8/10 1/10 14.69 [ 2.64, 81.79 ]
0.002 0.1 1 10 500
Favours polyurethane Favours dacron
Analysis 5.5. Comparison 5 Above-knee polyurethane (PUR) versus all other graft materials, Outcome 5
Secondary patency at 6 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 5 Above-knee polyurethane (PUR) versus all other graft materials
Outcome: 5 Secondary patency at 6 months
Study or subgroup Polyurethane Dacron
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Gloor 1996 8/10 1/10 14.69 [ 2.64, 81.79 ]
0.001 0.01 0.1 1 10 100 1000
Favours polyurethane Favours dacron
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Analysis 5.6. Comparison 5 Above-knee polyurethane (PUR) versus all other graft materials, Outcome 6
Secondary patency at 12 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 5 Above-knee polyurethane (PUR) versus all other graft materials
Outcome: 6 Secondary patency at 12 months
Study or subgroup Polyurethane Dacron
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Gloor 1996 9/10 2/10 14.69 [ 2.64, 81.79 ]
0.001 0.01 0.1 1 10 100 1000
Favours polyurethane Favours dacron
Analysis 6.1. Comparison 6 Below-knee PTFE versus all other graft materials, Outcome 1 Primary patency
at 6 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 6 Below-knee PTFE versus all other graft materials
Outcome: 1 Primary patency at 6 months
Study or subgroup PTFE Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 PTFE v ringed PTFE
Gupta 1991 5/24 3/20 11.3 % 1.47 [ 0.32, 6.71 ]
Subtotal (95% CI) 24 20 11.3 % 1.47 [ 0.32, 6.71 ]
Total events: 5 (PTFE), 3 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
2 PTFE v PTFE with vein cuff
SCAMICOS 2010 23/69 38/102 64.8 % 0.84 [ 0.45, 1.59 ]
Stonebridge 1997 6/37 3/39 13.7 % 2.24 [ 0.56, 8.92 ]
Subtotal (95% CI) 106 141 78.6 % 1.00 [ 0.56, 1.78 ]
Total events: 29 (PTFE), 41 (Other graft material)
0.001 0.01 0.1 1 10 100 1000
Favours PTFE Favours other graft type
(Continued . . . )
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(. . . Continued)
Study or subgroup PTFE Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Heterogeneity: Chi2 = 1.58, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 0.00 (P = 1.0)
3 PTFE v FUSION BIOLINE
Lumsden 2015 5/14 3/14 10.1 % 1.96 [ 0.39, 9.83 ]
Subtotal (95% CI) 14 14 10.1 % 1.96 [ 0.39, 9.83 ]
Total events: 5 (PTFE), 3 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
Total (95% CI) 144 175 100.0 % 1.12 [ 0.67, 1.87 ]
Total events: 39 (PTFE), 47 (Other graft material)
Heterogeneity: Chi2 = 2.31, df = 3 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Chi2 = 0.74, df = 2 (P = 0.69), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours PTFE Favours other graft type
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Analysis 6.2. Comparison 6 Below-knee PTFE versus all other graft materials, Outcome 2 Primary patency
at 12 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 6 Below-knee PTFE versus all other graft materials
Outcome: 2 Primary patency at 12 months
Study or subgroup PTFE Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 PTFE v Dacron
Post 2001 4/23 7/22 12.6 % 0.47 [ 0.12, 1.79 ]
Subtotal (95% CI) 23 22 12.6 % 0.47 [ 0.12, 1.79 ]
Total events: 4 (PTFE), 7 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
2 PTFE v PTFE with vein cuff
SCAMICOS 2010 27/61 47/93 55.0 % 0.78 [ 0.41, 1.48 ]
Stonebridge 1997 12/33 8/37 21.4 % 2.04 [ 0.73, 5.72 ]
Subtotal (95% CI) 94 130 76.4 % 1.02 [ 0.59, 1.76 ]
Total events: 39 (PTFE), 55 (Other graft material)
Heterogeneity: Chi2 = 2.40, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 0.07 (P = 0.94)
3 PTFE v ringed PTFE
Gupta 1991 6/19 4/17 11.0 % 1.48 [ 0.35, 6.24 ]
Subtotal (95% CI) 19 17 11.0 % 1.48 [ 0.35, 6.24 ]
Total events: 6 (PTFE), 4 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
Total (95% CI) 136 169 100.0 % 0.96 [ 0.60, 1.55 ]
Total events: 49 (PTFE), 66 (Other graft material)
Heterogeneity: Chi2 = 3.90, df = 3 (P = 0.27); I2 =23%
Test for overall effect: Z = 0.16 (P = 0.88)
Test for subgroup differences: Chi2 = 1.50, df = 2 (P = 0.47), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours PTFE Favours other graft type
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Analysis 6.3. Comparison 6 Below-knee PTFE versus all other graft materials, Outcome 3 Primary patency
at 24 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 6 Below-knee PTFE versus all other graft materials
Outcome: 3 Primary patency at 24 months
Study or subgroup PTFE Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 PTFE v Dacron
Post 2001 5/18 11/22 17.0 % 0.41 [ 0.12, 1.42 ]
Subtotal (95% CI) 18 22 17.0 % 0.41 [ 0.12, 1.42 ]
Total events: 5 (PTFE), 11 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
2 PTFE v PTFE with vein cuff
SCAMICOS 2010 31/53 51/83 54.5 % 0.88 [ 0.44, 1.78 ]
Stonebridge 1997 18/22 16/24 15.8 % 2.16 [ 0.59, 7.94 ]
Subtotal (95% CI) 75 107 70.3 % 1.08 [ 0.58, 2.01 ]
Total events: 49 (PTFE), 67 (Other graft material)
Heterogeneity: Chi2 = 1.39, df = 1 (P = 0.24); I2 =28%
Test for overall effect: Z = 0.25 (P = 0.80)
3 PTFE v ringed PTFE
Gupta 1991 7/14 6/14 12.6 % 1.32 [ 0.31, 5.67 ]
Subtotal (95% CI) 14 14 12.6 % 1.32 [ 0.31, 5.67 ]
Total events: 7 (PTFE), 6 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Total (95% CI) 107 143 100.0 % 0.94 [ 0.56, 1.57 ]
Total events: 61 (PTFE), 84 (Other graft material)
Heterogeneity: Chi2 = 3.52, df = 3 (P = 0.32); I2 =15%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Chi2 = 2.13, df = 2 (P = 0.35), I2 =6%
0.001 0.01 0.1 1 10 100 1000
Favours PTFE Favours other graft type
96Graft type for femoro-popliteal bypass surgery (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.4. Comparison 6 Below-knee PTFE versus all other graft materials, Outcome 4 Primary patency
at 36 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 6 Below-knee PTFE versus all other graft materials
Outcome: 4 Primary patency at 36 months
Study or subgroup PTFE Other graft material
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 PTFE v PTFE with vein cuff
SCAMICOS 2010 32/47 55/74 0.74 [ 0.33, 1.65 ]
0.002 0.1 1 10 500
Favours PTFE Favours other graft type
Analysis 6.5. Comparison 6 Below-knee PTFE versus all other graft materials, Outcome 5 Secondary
patency at 3 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 6 Below-knee PTFE versus all other graft materials
Outcome: 5 Secondary patency at 3 months
Study or subgroup PTFE Other graft material
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 PTFE v HUV
Eickhoff 1987 13/36 6/39 2.95 [ 1.05, 8.30 ]
0.001 0.01 0.1 1 10 100 1000
Favours PTFE Favours other graft type
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Analysis 6.6. Comparison 6 Below-knee PTFE versus all other graft materials, Outcome 6 Secondary
patency at 6 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 6 Below-knee PTFE versus all other graft materials
Outcome: 6 Secondary patency at 6 months
Study or subgroup PTFE Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 PTFE v HUV
Eickhoff 1987 16/36 7/35 32.3 % 3.01 [ 1.12, 8.07 ]
Subtotal (95% CI) 36 35 32.3 % 3.01 [ 1.12, 8.07 ]
Total events: 16 (PTFE), 7 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.029)
2 PTFE v PTFE with vein cuff
SCAMICOS 2010 17/69 30/102 67.7 % 0.79 [ 0.40, 1.56 ]
Subtotal (95% CI) 69 102 67.7 % 0.79 [ 0.40, 1.56 ]
Total events: 17 (PTFE), 30 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
Total (95% CI) 105 137 100.0 % 1.21 [ 0.69, 2.13 ]
Total events: 33 (PTFE), 37 (Other graft material)
Heterogeneity: Chi2 = 4.78, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Chi2 = 4.78, df = 1 (P = 0.03), I2 =79%
0.001 0.01 0.1 1 10 100 1000
Favours PTFE Favours other graft type
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Analysis 6.7. Comparison 6 Below-knee PTFE versus all other graft materials, Outcome 7 Secondary
patency at 12 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 6 Below-knee PTFE versus all other graft materials
Outcome: 7 Secondary patency at 12 months
Study or subgroup PTFE Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 PTFE v HUV
Eickhoff 1987 24/51 13/50 32.4 % 2.46 [ 1.10, 5.49 ]
Subtotal (95% CI) 51 50 32.4 % 2.46 [ 1.10, 5.49 ]
Total events: 24 (PTFE), 13 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.029)
2 PTFE v PTFE with vein cuff
SCAMICOS 2010 26/61 40/93 49.7 % 0.98 [ 0.51, 1.89 ]
Stonebridge 1997 10/33 7/37 17.8 % 1.84 [ 0.62, 5.46 ]
Subtotal (95% CI) 94 130 67.6 % 1.16 [ 0.66, 2.03 ]
Total events: 36 (PTFE), 47 (Other graft material)
Heterogeneity: Chi2 = 0.94, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
Total (95% CI) 145 180 100.0 % 1.48 [ 0.94, 2.34 ]
Total events: 60 (PTFE), 60 (Other graft material)
Heterogeneity: Chi2 = 3.18, df = 2 (P = 0.20); I2 =37%
Test for overall effect: Z = 1.68 (P = 0.094)
Test for subgroup differences: Chi2 = 2.24, df = 1 (P = 0.13), I2 =55%
0.001 0.01 0.1 1 10 100 1000
Favours PTFE Favours other graft type
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Analysis 6.8. Comparison 6 Below-knee PTFE versus all other graft materials, Outcome 8 Secondary
patency at 24 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 6 Below-knee PTFE versus all other graft materials
Outcome: 8 Secondary patency at 24 months
Study or subgroup PTFE Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 PTFE v HUV
Eickhoff 1987 36/50 16/38 33.2 % 3.40 [ 1.45, 7.97 ]
Subtotal (95% CI) 50 38 33.2 % 3.40 [ 1.45, 7.97 ]
Total events: 36 (PTFE), 16 (Other graft material)
Heterogeneity: not applicable
Test for overall effect: Z = 2.81 (P = 0.0050)
2 PTFE v PTFE with vein cuff
SCAMICOS 2010 29/53 45/82 50.6 % 0.99 [ 0.50, 1.98 ]
Stonebridge 1997 17/22 14/24 16.2 % 2.32 [ 0.69, 7.88 ]
Subtotal (95% CI) 75 106 66.8 % 1.22 [ 0.67, 2.23 ]
Total events: 46 (PTFE), 59 (Other graft material)
Heterogeneity: Chi2 = 1.41, df = 1 (P = 0.24); I2 =29%
Test for overall effect: Z = 0.65 (P = 0.51)
Total (95% CI) 125 144 100.0 % 1.72 [ 1.05, 2.80 ]
Total events: 82 (PTFE), 75 (Other graft material)
Heterogeneity: Chi2 = 5.10, df = 2 (P = 0.08); I2 =61%
Test for overall effect: Z = 2.15 (P = 0.031)
Test for subgroup differences: Chi2 = 3.69, df = 1 (P = 0.05), I2 =73%
0.001 0.01 0.1 1 10 100 1000
Favours PTFE Favours other graft type
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Analysis 6.9. Comparison 6 Below-knee PTFE versus all other graft materials, Outcome 9 Secondary
patency at 36 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 6 Below-knee PTFE versus all other graft materials
Outcome: 9 Secondary patency at 36 months
Study or subgroup PTFE Other graft material
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 PTFE v PTFE with vein cuff
SCAMICOS 2010 31/47 52/74 0.82 [ 0.37, 1.80 ]
0.001 0.01 0.1 1 10 100 1000
Favours PTFE Favours other graft type
Analysis 6.10. Comparison 6 Below-knee PTFE versus all other graft materials, Outcome 10 Limb salvage
at 12 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 6 Below-knee PTFE versus all other graft materials
Outcome: 10 Limb salvage at 12 months
Study or subgroup PTFE PTFE with vein cuff
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 PTFE v PTFE with vein cuff
SCAMICOS 2010 16/61 22/93 72.0 % 1.15 [ 0.54, 2.42 ]
Stonebridge 1997 8/33 5/38 28.0 % 2.08 [ 0.63, 6.88 ]
Total (95% CI) 94 131 100.0 % 1.35 [ 0.72, 2.55 ]
Total events: 24 (PTFE), 27 (PTFE with vein cuff)
Heterogeneity: Chi2 = 0.68, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours PTFE Favours PTFE % vein cuff
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Analysis 6.11. Comparison 6 Below-knee PTFE versus all other graft materials, Outcome 11 Limb salvage
at 24 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 6 Below-knee PTFE versus all other graft materials
Outcome: 11 Limb salvage at 24 months
Study or subgroup PTFE Other graft material
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 PTFE v PTFE with vein cuff
SCAMICOS 2010 19/54 22/73 68.7 % 1.26 [ 0.59, 2.66 ]
Stonebridge 1997 9/33 7/36 31.3 % 1.54 [ 0.51, 4.68 ]
Total (95% CI) 87 109 100.0 % 1.34 [ 0.72, 2.49 ]
Total events: 28 (PTFE), 29 (Other graft material)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours PTFE Favours PTFE % vein cuff
Analysis 7.1. Comparison 7 Below-knee heparin bonded Dacron versus all other graft materials, Outcome 1
Primary patency at 3 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 7 Below-knee heparin bonded Dacron versus all other graft materials
Outcome: 1 Primary patency at 3 months
Study or subgroup HBD PTFE
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 HBD v PTFE
Devine 2004 5/15 6/15 0.76 [ 0.18, 3.26 ]
0.001 0.01 0.1 1 10 100 1000
Favours HBD Favours PTFE
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Analysis 7.2. Comparison 7 Below-knee heparin bonded Dacron versus all other graft materials, Outcome 2
Primary patency at 6 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 7 Below-knee heparin bonded Dacron versus all other graft materials
Outcome: 2 Primary patency at 6 months
Study or subgroup HBD PTFE
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 HBD v PTFE
Devine 2004 6/15 9/15 0.46 [ 0.11, 1.89 ]
0.001 0.01 0.1 1 10 100 1000
Favours HBD Favours PTFE
Analysis 7.3. Comparison 7 Below-knee heparin bonded Dacron versus all other graft materials, Outcome 3
Primary patency at 12 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 7 Below-knee heparin bonded Dacron versus all other graft materials
Outcome: 3 Primary patency at 12 months
Study or subgroup HBD PTFE
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 HBD v PTFE
Devine 2004 9/15 10/15 0.76 [ 0.18, 3.26 ]
0.001 0.01 0.1 1 10 100 1000
Favours HBD Favours PTFE
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Analysis 7.4. Comparison 7 Below-knee heparin bonded Dacron versus all other graft materials, Outcome 4
Primary patency at 24 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 7 Below-knee heparin bonded Dacron versus all other graft materials
Outcome: 4 Primary patency at 24 months
Study or subgroup HBD PTFE
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 HBD v PTFE
Devine 2004 11/15 12/15 0.70 [ 0.13, 3.68 ]
0.001 0.01 0.1 1 10 100 1000
Favours HBD Favours PTFE
Analysis 7.5. Comparison 7 Below-knee heparin bonded Dacron versus all other graft materials, Outcome 5
Primary patency at 60 months.
Review: Graft type for femoro-popliteal bypass surgery
Comparison: 7 Below-knee heparin bonded Dacron versus all other graft materials
Outcome: 5 Primary patency at 60 months
Study or subgroup HBD PTFE
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 HBD v PTFE
Devine 2004 12/15 15/15 0.12 [ 0.01, 1.22 ]
0.001 0.01 0.1 1 10 100 1000
Favours HBD Favours PTFE
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
Search run on Mon Mar 13 2017
#1 MESH DESCRIPTOR Arteriosclerosis 869
#2 MESH DESCRIPTOR Arteriolosclerosis EX-
PLODE ALL TREES
0
#3 MESH DESCRIPTOR Arteriosclerosis Oblit-
erans
72
#4 MESH DESCRIPTOR Atherosclerosis 641
#5 MESHDESCRIPTORArterialOcclusiveDis-
eases
734
#6 MESH DESCRIPTOR Intermittent Claudi-
cation
723
#7 MESH DESCRIPTOR Ischemia 801
#8 MESH DESCRIPTOR Peripheral Vascular
Diseases EXPLODE ALL TREES
2229
#9 (atherosclero* or arteriosclero* or PVD or
PAOD or PAD ):TI,AB,KY
9491
#10 ((arter* or vascular or vein* or veno* or pe-
ripher*) near3 (occlus* or reocclus* or re-oc-
clus* or steno* or restenos* or obstruct* or lesio*
or block* or harden* or stiffen* or obliter*) ):
TI,AB,KY
8366
#11 (peripheral near3 dis*):TI,AB,KY 3525
#12 (claudic* or IC):TI,AB,KY 3219
#13 (isch* or CLI):TI,AB,KY 24757
#14 arteriopathic:TI,AB,KY 7
#15 dysvascular*:TI,AB,KY 11
#16 (leg near3 (occlus* or reocclus* or re-occlus*
or steno* or restenos* or obstruct* or lesio* or
99
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(Continued)
block* or harden* or stiffen* or obliter*) ):TI,
AB,KY
#17 (limb near3 (occlus* or reocclus* or re-occlus*
or steno* or restenos* or obstruct* or lesio* or
block* or harden* or stiffen* or obliter*) ):TI,
AB,KY
157
#18 ((lower near3 extrem*) near3 (occlus* or reoc-
clus* or re-occlus* or steno* or restenos* or ob-
struct* or lesio* or block* or harden* or stiffen*
or obliter*) ):TI,AB,KY
81
#19 MESH DESCRIPTOR Leg EXPLODE ALL
TREES WITH QUALIFIERS BS
1113
#20 MESH DESCRIPTOR Popliteal Artery 280
#21 MESH DESCRIPTOR Femoral Artery 826
#22 (femor* or popliteal or fempop* or poplite* or
infrapopliteal or femdist* or infrainquinal or
infra-inquinal) :TI,AB,KY
9481
#23 ((above or below) near2 knee) 486
#24 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #
7OR #8 OR #9 OR #10 OR #11 OR #12 OR
#13 OR #14 OR #15 OR #16 OR #17 OR #
18 OR #19 OR #20 OR #21 OR #22 or #23
52728
#25 MESH DESCRIPTOR Blood Vessel Prosthe-
sis EXPLODE ALL TREES
411
#26 MESH DESCRIPTOR Blood Vessel Prosthe-
sis Implantation EXPLODE ALL TREES
405
#27 (bypass or surgery or construct* or reconstruct*
or re-construct* or re-vasculari* or revasculari*
or graft* ):TI,AB,KY
139976
#28 #25 or #26 or #27 140022
#29 #24 and #28 14350
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Appendix 2. Trials registries searches
ClinicalTrials.gov
354 studies found for: Peripheral Vascular Diseases OR Arterial Occlusive Diseases OR Ischemia | bypass AND (graft OR Polytetraflu-
oroethylene OR dacron OR polyester OR dacron OR umbilical OR PTFE)
World Health Organization International Clinical Trials Registry Platform
44 records for 36 trials found
bypass AND (graft OR Polytetrafluoroethylene OR dacron OR polyester OR dacron OR umbilical OR PTFE) in title
AND
Peripheral Vascular Diseases OR Arterial Occlusive Diseases OR Ischemia in Condition
ISRCTN Register
2 results for
(Peripheral Vascular Diseases OR Arterial Occlusive Diseases OR Ischemia) AND bypass AND (graft OR Polytetrafluoroethylene OR
dacron OR umbilical OR PTFE)
WH A T ’ S N E W
Last assessed as up-to-date: 13 March 2017.
Date Event Description
13 March 2017 New citation required but conclusions have not changed Search updated. Seven new studies included, six new
studies excluded and twonewongoing studies identified.
Text updated to reflect recent Cochrane standards. All
included studies assessed for risk of bias usingCochrane’s
’Risk of bias’ tool. ’Summary of findings’ table added.
No change to conclusions
13 March 2017 New search has been performed Search updated and seven new studies included, six new
studies excluded and two new ongoing studies identified
H I S T O R Y
Review first published: Issue 2, 1999
Date Event Description
10 March 2010 New citation required and conclusions have changed Review updated by new authors. Eight additional trials
included and four trials which were included in the
previous version of the review excluded
1 September 2008 Amended Converted to new review format.
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C O N T R I B U T I O N S O F A U T H O R S
GA: identified relevant trials, assessed quality for all included trials, extracted data and updated the text of review.
CT: identified relevant trials, assessed quality, extracted data, wrote text of previous version of review, and reviewed updated text.
D E C L A R A T I O N S O F I N T E R E S T
GA: has declared that he previously held a National Institute for Health Research Academic clinical fellowship (2011-2014) and that
he received funds for a grant from Heath and Care Research Wales regarding research for patient and public benefit (grant number
1198); there are no known conflicts of interest with this review.
CT: has declared that he received money from Cook Medical for travel/accommodation/meeting expenses unrelated to this review and
that he received funds for a grant from Heath and Care ResearchWales regarding research for patient and public benefit (grant number
1198); there are no known conflicts of interest with this review.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Chief Scientist Office, Scottish Government Health Directorates, The Scottish Government, UK.
The editorial base of Cochrane Vascular is supported by the Chief Scientist Office.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
For this update, the risk of bias in all included studies was assessed using Cochrane’s ’Risk of bias’ tool and a ’Summary of findings’
table has been added.
We reworded the objective so to adhere better to the Cochane guidelines.
We amended the ’types of studies’ to include all possible graft types.
We provided definitions of the outcomes primary and secondary patency.
We analysed and presented data into groups according to whether the distal anastomosis was above or below the knee.
I N D E X T E R M S
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Medical Subject Headings (MeSH)
Arterial Occlusive Diseases [∗surgery]; Blood Vessel Prosthesis Implantation; Femoral Artery [∗surgery]; Intermittent Claudication
[surgery]; Leg [∗blood supply]; Polyethylene Terephthalates; Polytetrafluoroethylene; Popliteal Artery [∗surgery]; Randomized Con-
trolled Trials as Topic; Saphenous Vein [∗transplantation]; Transplantation, Autologous; Umbilical Veins [∗transplantation]; Vascular
Surgical Procedures
MeSH check words
Humans
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